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ABSTRACT 
Current trend in evaluating dermatological formulations is 
shifting towards measuring the retention of drugs in the skin 
rather than flux through the skin. This study was undertaken 
to emphasize the importance of drug retention and to 
investigate possible factors which affect it. 
An in vivo hairless rat model was used in this study to 
evaluate the effect of 26 vehicles on the local drug delivery 
to the skin layers. For this purpose, two model drugs, 3H-
Hydrocortisone (HC) and 3H-triamcinolone acetonide (TAC) , were 
used. Vehicles selected belonged to seven different classes 
including glycols, polyglycols, alcohols, esters, glycerides, 
mixed commercial vehicles and enhancers. 
Solubilities of HC and TAC were determined in these vehicles 
using an HPLC method. The solubility data showed large ranges, 
1912 fold for HC and 2297 for TAC, indicating a need to 
evaluate the influence of solubility on the skin uptake of 
these drugs. 
In vivo retention studies were carried out in the hairless rat 
model using the "finite dose" approach. The drug uptake in the 
tissue was expressed in terms of µg of drug per gm of tissue 
and percent of applied dose retained in the skin layer. These 
data were then categorized into various classes of the 
ii 
vehicles used and the following findings were observed: 
• Retention of HC and TAC in the epidermis and dermis was 
affected dramatically by the choice of vehicles. 
• The overall rank orders and ranges were different for 
epidermal and dermal retention for both drugs indicating 
that the vehicle effects are different for the epidermis 
and dermis. 
• In most cases the rank orders and ranges within different 
classes of vehicles was different for both drugs. 
• Ratios of epidermal to dermal 
differently for HC and TAC. 
retention ranked 
The foregoing observations e.g. differing rank orders and 
ranges, lead us to recommend the use of retention data instead 
of flux data in screening vehicles for optimizing 
dermatological formulations for these two drugs. 
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PREFACE 
This thesis has been written in a standard format. It consist 
of a systematic study to evaluate the effect of vehicles on 
the in vivo drug delivery to the skin layers. It has been 
subdivided into seven sections. 
The first section introduces the subject of topical drug 
delivery and the effect of vehicles. This is followed by a 
section on objectives. The experimental techniques are 
discussed in the third section. The results obtained are 
discussed in the fourth section. The entire work is summarised 
in the fifth section. References are in the sixth section 
followed by appendices which consist of raw data tables. The 
last section consists of bibliography. 
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1. INTRODUCTION 
Drug substances are administered through various routes to 
obtain either systemic or local therapeutic effects. For 
systemic effects, drugs are delivered into the blood stream by 
administering them via the parenteral, oral, nasal, ocular, 
vaginal, and rectal routes. Recently, the skin has been used 
for the systemic drug delivery by using transdermal products. 
For local effects, drugs are applied on the surface of the 
affected tissue. Topical products include ophthalmic, nasal, 
auricular, buccal, vaginal, dermatological, and rectal 
products. These products can be apparently termed as targeted 
drug delivery systems because they provide drugs at the site 
of action. All products designed to provide local therapeutic 
effects can be termed as topical products. 
The principles involved in transdermal and dermatological 
products have often been mistakenly used interchangeably. 
Transdermal products are designed to provide maximum transport 
of drugs across the skin into the blood stream with no or 
minimal drug retention in the skin layers. Dermatological 
products on the other hand are designed with an opposite 
purpose, i.e. to obtain a maximal drug retention in the skin 
layers with no or minimal drug transport across the skin in 
the blood stream. Thus, different pharmacokinetic principles 
are involved in these two types of drug products. Besides 
1 
pharmacokinetic principles, the 
involved are also quite different. 
formulation principles 
Although dermatological products have been in existence for 
tens of decades, the mechanistic aspects of drug delivery to 
the skin layers and scientific principles to optimize it, and 
predictive selection of optimal vehicles/excipients have not 
been well studied and understood. This is true mainly because 
the emphasis has long been placed on the optimization of 
cosmetic/aesthetic and toxicological properties of 
dermatological products. Selection of vehicles/excipients was 
based primarily on these two parameters. Until quite recently, 
the critical importance of optimal drug delivery to the skin 
and its relation to therapeutic effect was all but ignored. 
Principles involved in the design of transdermal products have 
been studied for over two decades and are well understood. As 
the momentum in the development of transdermal products 
increased, researchers began to realize the importance of 
local drug delivery for dermatological products. But, 
unfortunately, this was done by using scientific principles 
applicable to transdermal products. Awareness of this issue 
became clear at two recent international workshops 1 • 2 on the 
optimal development of dermatological drug products. 
Optimal local drug delivery from dermatological products is 
2 
( 
( 
vital to obtain desired therapeutic effects. To accomplish 
this, selection of formulation vehicles/excipients is 
critically important. It is necessary to optimize local drug 
delivery prior to testing formulations in the clinic. If 
desired efficacy is not obtained, further efforts should be 
made to improve drug delivery. The improved formulation (s) 
should be tested again in the clinic. This feed-back cycle 
would allow a proper interpretation of clinical data and 
development of an optimal product. 
1.1. Properties of Skin Relevant to Drug Delivery: 
Skin is the most exposed and the largest organ in the human 
body. It is also a complex and sophisticated organ we do not 
know much about. The origin and the causes of many 
dermatological diseases are not understood. The precise 
targets in the skin layers responsible for ailments and site 
of action of drugs are usually not known. It is quite a 
challenge for a pharmaceutical scientist who develops 
formulations and the dermatologist who uses it on patients. 
The major function of the skin is that of a protective organ. 
It is supposed to, among other functions, protect the body 
against environmental hazards by keeping harmful chemicals 
from absorbing through the skin into the systemic circulation. 
It also prevents water loss from the body, a function which is 
3 
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vital to the human survival 3 • The skin is not meant for the 
intake of substances. The objectives involved in developing 
either transdermal or dermatological products are against this 
property of the skin, i.e. to overcome the natural barrier 
properties of the skin. 
The skin is a multilayered 
stratum corneum, together 
organ3 • The 
with the 
outermost 
underlying 
layer, 
viable 
epidermis, functions as a protective layer preventing water 
loss as well as the absorption of foreign matter from the 
environment. The stratum corneum plus the viable epidermis can 
also be called "epidermis". The dermal components also provide 
elasticity and flexibility to the skin. Together, the stratum 
corneum, viable epidermis and particularly the dermis provide 
a firm and durable envelop which coupled with the underlying 
fatty tissues give form and necessary structure and 
flexibility to the skin. 
4 
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Figure 1 
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1.1.1. Epidermis: The upper layer of the skin is called as the 
epidermis5 • The basal cell layer (Stratum Germinativum) 
comprises 90 % of the epidermal cells. This layer is 
responsible for the formation of the protective layer (Stratum 
Corneum) which provides a barrier to the uptake of pathogens, 
prevents water loss and is abrasion resistant. The basal cells 
undergo a programmed process of cell division in which the 
undifferentiated cells are converted to highly differentiated, 
non-living cells. Basal cell proliferation is regulated by a 
variety of intrinsic and extrinsic factors which are not fully 
understood4 . The spinous layer (Stratum Spinosum) is situated 
directly above the basal cells. These cells are biochemically 
distinct in the sense that they synthesize a different set of 
macromolecules6 • This layer is called as the spinous layer 
because of its spiny like appearance. The granular layer 
(Stratum Granulosum) consists of living cells. These cells 
contain electron-dense keratohyalin granules that contain 
profilagrin. The transition zone (Stratum Lucidum) is situated 
between the granular and cornified layers. It is a transition 
zone between living and dead epidermis. This is a zone of 
excessive cellular remodeling. Most of the existing cellular 
organelles, DNA and RNA, are destroyed by the activity of 
proteases and nucleases. The lipid contents of the membranes 
coating granules are released into the extracellular matrix, 
the keratin filaments are restructured to a more stable form 
and the cornified envelop is formed. The cornified layer 
6 
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(Stratum Corneum) is the last stage of keratinocyte 
differentiation and is made up of corneocytes. The 
corneocytes are shaped as flattened polyhedrons and are held 
together by modified desmosomes and an interlocking system of 
ridges and grooves. The major protein component of the 
corneocyte is keratin structured into macrofibrillar bundles. 
Another major component is the cornified envelop which 
consists of a covalently crosslinked sheet of protein. This 
layer also contains various lipids on the surface formed by 
the excretion of sebum emanating from the sebaceous glands 
which help in protecting the body against environmental 
chemicals/substances. The stratum corneum of various species 
including murine, porcine, rodent and humans was studied and 
it was concluded that the majority of lipids consisted of 
sphingolipids. Other lipid components of relatively lesser 
importance include cholesterol, triglycerides and fatty 
acids 7 ' 8 ' 9 • 
Two other cell types which populate the epidermis are the 
Merkel cells and the Melanocytes. The function of Merkel cells 
is not well understood, although it is believed that these 
cells contain neurotransmitters and may function as a 
communication point between surrounding keratinocytes and 
neurons. Melanocytes are pigment producing cells which 
originate i n the neural crest and are distributed among the 
basal keratinocytes. Melanin produced in melanosome and 
7 
featured in melanocytes provides the skin color4 • 
1.1.2. Dermis: The dermis comprises the largest fraction of 
the skin and is responsible for providing its structural 
strength. It consists of elastin which serves as the 
connective tissue. It also provides an environment for nerve 
and vascular network and appendages needed to support the 
epidermis. The major dermal cell types are fibroblasts, 
macrophages, and mast cells, although other cell types, e . g. 
lymphocytes, plasma cells, etc. frequently populate the dermis 
in response to injury and other stimuli. The fibroblast is 
responsible for the synthesis and destruction of the 
connective tissue proteins. Fibroblasts secrete collagen and 
elastin which in turn secrete collegenase and gelatinase which 
remodel collagen fibrils 10 • Macrophages originate as precursor 
cells in bone marrow, mature into monocytes in the blood, and 
terminally differentiate to macrophage in the tissue. Their 
main function is to process and present antigens to 
immunocompetent lymphoid cells. They also synthesize and 
secrete interleukin 1 (IL-1), growth factors, prostaglandins, 
and interferon6 • Mast cells are present in all layers of the 
dermis with focal concentration around blood vessels. They 
produce granules full of histamine which is vasoactive. Mast 
cells respond to light, cold, acute trauma, vibration, and 
pressure, as well as chemical and immunological stimuli. When 
8 
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triggered by these stimuli, they release histamine from the 
granules initiating irritation and/or sensitization11 • 
In Figure 2, a schematic and more complete structure of the 
skin is displayed4 • In addition to the epidermis and dermis, 
this structure shows hair follicle, hair shaft, sebaceous 
gland, dermal and subcutaneous vasculature, and eccrine gland. 
Besides their pharmacological significance, these structures 
also play an important role in defining drug delivery 
pathways. 
9 
,.._. 
0 
~ 
SJ1olum 
Ot1 n•l1 
llOOO · .1000/""' 
Subculoncout 
lolly li11ut 
loll1dt 
:.: 1= . :: .1-. 
SulJc ulonr ov' I fi;<, .· 
- l ... 
votculol\Jlt __ ·_,_·  
Io I 
1101, 
,ho If 
SrLorcou1 Oumol 
qlonJ Y01Culolu1c 
' Lj ___ ~!-°' __ 
"'' H 101 n 
pdo1uni 
fl\U IC It 
[cc11n t 
qlond 
\ 
' 
' \ 
\ 
' \ 
' 
' \ 
\ 
\ 
Figure 2. 
the Skin 
Detailed Representation of 
Layers (Adapted From Eckert, 
' \ 
llo) 
the 
R. 
Mic roscopic 
L., 1992) 1 . 
Structure of 
SltOlum 
(OIO(Ufrl 
LIYHH,J 
f piJttmtt 
J 
( 
( 
1.2. Definitions Pertaining to the Transport of Drug To and 
Through the Skin 
Permeation is defined as net transport of drugs across the 
skin into the systemic circulation1 2 • This term is relevant to 
transdermal products where formulation is applied in an 
infinite (reservoir) dose manner. Other comparable terms are 
absorption and transport. Permeation has been expressed 
quantitatively either as percent absorption, percent 
permeated, or permeability coefficient13 • The last term is 
often used in describing transdermal drug delivery. Percent 
absorption is not a meaningful expression for transdermal 
products. One can carry out in vivo or in vitro transdermal 
experiments in order to optimize formulations. Fast permeation 
and clearance are desired features for an optimal product. In 
vivo animal studies are carried out by applying the 
formulation in a patch to the abdominal skin of the model 
animal used. The drug transport across the skin is calculated 
by measuring the blood levels for the drug. In vitro studies 
are carried out by placing a piece of the model skin between 
two halves of a diffusion cell. Various diffusion cells have 
been designed and modified to provide accurate determinations 
of penetrant flux14 • The upper half of the diffusion cell is 
called as the "donor" compartment. The formulation to be 
tested is placed in this compartment. Since a reservoir of the 
formulation is maintained in the donor compartment throughout 
the experiment the drug concentration remains more or less 
11 
( 
constant for the length of the experiment. That is why these 
types of experiments are called as 11 infinite 11 dose 
experiments. They are also sometimes termed as 11 flux 11 
studies15 • 16 • 17 • Some researchers have tried to model the 
transport processes by considering the individual role of the 
skin layers e.g. stratum corneum, epidermis and dermis Such 
approaches were used to mathematically predict the 
percutaneous permeation of betamethasone 17-valerate through 
human skin 18 
Retention is defined as drug residence in the skin layers or 
drug localization in the skin. This term is relevant to 
dermatological products when formulation is applied in a 
finite dose manner (one-three mg/cm2 ) • A comparable term is 
penetration. Retention can be expressed quantitatively as drug 
concentration in the skin e.g. µg/gm (whole skin, epidermis or 
dermis) or as a percent of the dose applied 12 • One can carry 
out in vivo or in vitro experiments to optimize the 
dermatological formulations. In vivo studies are carried out 
by applying dermatological formulations on the abdominal 
region and excising the skin after a certain period of time. 
The time of the experiment may vary with different 
researchers. The animal is sacrificed at the end of the 
experiment and the skin is excised. Drug concentration can be 
expressed in the whole skin or in individual layers e.g. 
epidermis and dermis. The skin may be sectioned into 
12 
individual layers by using a microwave technique19 or by 
microtome slicing of the skin20 • Since only 1-3 mg of the 
formulation is applied per cm2 these type of experiments are 
termed as the "finite" dose experiments 1,2,19-23 
Figure 3 shows a more composite schematic representation of 
the local events which take place upon the application of a 
transdermal or dermatological preparation on the skin 
surface3 • This diagram efficiently depicts the fate of a drug 
when it is released/liberated from the applied dermatological 
or transdermal formulation. 
Although using the human in vivo model would be the best 
choice for evaluating both transdermal and dermatological 
products it is impractical to use primarily because of the 
cost and other practical factors. However by using animal 
models which have the relevant skin characteristics similar to 
man can be successfully substituted for human studies for 
optimizing dermatological or transdermal formulations prior to 
clinical trials. As is explained in detail in the following 
sections a variety of animal models have been used. 
1.3. Assessment of Skin Permeation and Retention 
Over the decades, a large number of models, methods and 
membranes have been explored to assess drug delivery from 
13 
transdermal preparations. These models were designed to answer 
many questions including drug release from transdermal 
products, rates of drug transport across the skin, 
optimization of drug delivery by using 
14 
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Figure 3. Schematic Representation of Local Events After 
Application of a Transdermal or Dermatological Formulation 
(Adapted from Shaefer, H., et al., 1982. 3 ) 
15 
enhancers, mechanisms of drug transport, study of various 
factors which affect drug delivery and use of prodrugs. Most 
studies reported in the literature are related to transdermal 
drugs. 
Several types of animals have been explored as possible models 
for human skin. A rather interesting list compiled from these 
studies is provided in Table 1 24 
As can be seen, the animals explored range from mouse to 
horse. Of course all of these vastly varying animal skins can 
not possibly be the right model for the human skin. The 
criteria for comparability used in the reported studies 
included total percent permeation, permeability coefficients, 
blood levels, urine levels, and pharmacological and 
pharmacodynamic responses. This list may appear to be 
extraordinarily long, but it is by no means complete. However, 
it does provide an indication of diversity in a researcher's 
choice of animal models which presumably mimic the 
permeability of human skin. 
16 
Table 1. List of Animal Model s Used in Transdermal and 
Dermatological Drug Delivery24 • 
I # I Animals I In Vivo I In Vitro I References I 
1. Hairless Mouse x 25 
2. Swiss (Furry Mouse) x 26 
3. Athymic Nude Mouse x 24 
4. Furry Rat x x 27 
5. Fuzzy Rat x x 24 
6 . Nude Rat x x 28 
7. Hairless Rat x x 29, 30 
8. Hairless Guinea Pig x x 31 
9. Guinea Pig x x 32 
10 . Weanling Yorkshire Pig x 33 
11. Yucatan Miniature Pig x 34,35 
12. Mini Pig x 27 
13. Micro Pig x 24 
14. Domestic Pig x 36 
15 . Cat x 37 
16. Dog x 37 
17. Mexican Hairless Dog x 38 
18. Hairless Dog x 39 
19. Syrian Golden Hamster x 40 
20 . Sheep x 41 
21. Chimpanzee x x 37 
22. Rhesus Monkey x x 42 
23 . Squirrel Monkey x 27 
24 . Rabbit x x 30 
25 . Goat x 37 
26 . Horse x 37 
27. Snake (shed s kin) x 43,44 
1 7 
Skins from these models can be classified into the following 
three major categories: 
a. Furry skins 
b. Fuzzy skins 
c. Hairless skins 
Furry skins are not suitable models for human skin. Hairless 
skins provide the permeation and retention information which 
is mechanistically closer to the human skin. A review of 
literature indicates that different investigators have claimed 
that the permeability of a variety of skins resembles that of 
the human skin24 • The models referred to here can be classified 
as follows 21 : 
• 
• 
• 
Human In Vivo 
Animal In Vivo 
Cultured Skin Membranes 
• 
• 
• 
Human In Vitro 
Animal In Vitro 
Synthetic Membranes 
1.3.1 Human In Vivo: Estimation of a drug's permeation or 
retention using human in vivo model is, of course, most 
preferred. But, it is also the most difficult and non-
practical model to use. Rarely would one get an opportunity to 
routinely use this model during the development of a 
transdermal or dermatological product. Drug delivery 
assessment is invariably made by using non-human models. 
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However, towards the completion of the development, one should 
estimate drug delivery in humans. Efforts should be made at 
every opportunity one gets to use the human in viv o model so 
that a historical data base can be built for the correlation 
of human data with those from animal or other studies. 
1.3.2. Human In Vitro: A large number of studies have been 
reported on drug permeation through excised human skin, only 
a few will be referred here 41 ' 45 - 51 • These studies were done by 
placing a piece of the skin in between two halves of a 
diffusion/permeation apparatus and by monitoring drug 
transport into the receptor compartment . The in vitro 
approach has been used by many researchers in assessing the 
feasibility of developing transdermal products. It is 
important to note that in vitro data may not always correlate 
with in vivo data. Recently, some investigators have used this 
approach in evaluating dermatological products. As was pointed 
out at the International Workshops on Dermatological 
Products 1 • 2 this approach does not necessarily provide a 
correct answer to the question of drug delivery to the skin 
layers. Drug retention and not drug permeation is the correct 
and relevant criterion in evaluating dermatological products. 
It has been shown that the kinetics of drug permeation and 
retention are not necessarily correlated 19 • 21 - 2 3 • Permeation and 
retention of drugs can be differently influenced for different 
drugs by formulation factors. 
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Some scientists have used human in vitro models to evaluate 
dermatological products by monitoring drug retention in the 
skin layers at the end of a permeation experiment. This 
approach, in concept, is fine but, due to differences between 
in vivo and in vitro studies, one may not get correct and 
meaningful data. These differences can arise due to the 
following reasons: 
a. Inherent differences in the transport pathways. Certain 
transport pathways through the skin may behave 
differently in the in vitro vs in vivo situations. These 
pathways may include the follicles and sweat glands. 
b. Receptor compartment fluid can migrate upward into the 
donor compartment and change the characteristics of the 
applied formulation thus altering the permeation and 
retention properties of the applied drugs. 
c. The relative abilities of the epidermis and dermis to 
permeate and retain drugs can change due to the migration 
of receptor fluid into the skin layers. 
d. Drugs need to cross the entire skin thickness in the in 
vitro system. However, in the in vivo system, they start 
getting picked up by the circulation just past the viable 
epidermis and do not have to traverse the entire skin 
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tissue. This can provide differing permeation/retention 
data. 
e. The enhancing effects of most formulation excipients are 
likely to exert different effects in in vitro vs in vivo 
systems. 
While there are good reasons to use excised human skin, there 
are disadvantages: 
a. It is difficult to obtain human skin of a desirable age, 
gender, race, site and quality. Therefore, it is 
difficult and often not possible to keep these parameters 
constant in a given study. 
b. Invariably, the skin needs to be stored prior to use. 
Different investigators use different storage conditions 
which are likely to affect results. 
c. The skin has to be free from any contagious disease. This 
restricts the sources of skin supply. 
d. The cost considerations. 
1.3.3. Animal In Vivo: Animal in vivo studies are more 
desirable than in vitro studies due to their relevance. 
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However, such studies have not been extensively carried out 
and reported 28 • 29 • 52 - 55 These studies were concerning both 
transdermal and dermatological drugs. For the latter drugs, 
the criterion of drug delivery was drug concentration in the 
stratum corneum determined by using the tape stripping and 
autoradiographic technics. Recently, another i n vivo approach 
has been developed56 • This approach used an in vivo hairless 
guinea pig model and provided blood level data for transdermal 
compounds. By comparing results with the pharmacokinetics in 
humans, if known, or by making appropriate assumptions, one 
can predict blood levels in humans. This model has already 
been used successfully. 
Similarly, an in vivo model for dermatological drugs is 
preferred over an in vitro model. In this model, a formulation 
is applied in a finite dose manner and drug retention is 
determined in the epidermis and dermis. Various potential 
formulations can be evaluated and ranked meaningfully using 
such a model. A hairless guinea pig model has been developed 
and has been used extensively in screening dermatological 
formulations at Hoffmann-La Roche, Inc. for the past several 
years5 6 • The disadvantages of in vivo animal models include the 
cost involved and need for animal facilities. 
1.3.4. Animal In Vitro: This model has been extensively used 
in evaluating transdermal drugs. The model suffers from the 
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same disadvantages as those mentioned in the section, Human In 
Vitro. An additional concern is the morphological properties 
of the animal skins used in these studies. Most studies 
reported used furry skins. Mechanistic studies have shown that 
only 11 hairless 11 skins prov ide transport pathways comparable to 
the human skin24 • Hairless skins are not fully devoid of hair 
follicles. The residual follicles and the overall skin 
structure provide transport pathways and effects of 
physicochemical parameters similar to those found in the human 
skin. Data obtained from 11 furry 11 skins is irrelevant and non-
representative to human skin. 
Almost all of the reported studies using animal in vitro 
models pertain to transdermal drugs 27 ' 42 ' 57 - 59 • The use of excised 
animal skins in evaluating dermatological formulations for 
drug retention in the skin layers is rather limited1 9 • 20 • 22 • 23 • 
The results are greatly influenced by the artefact of using an 
in vitro system. Therefore, the use of in vitro animal models 
for dermatological drugs should be discouraged. 
1.3.5. Cultured membranes: Recently, a lot of research has 
been done by Organogenesis Inc. and Advanced Tissue Sciences 
in producing cultured skin60 • 61 • The cultured membranes were 
developed for grafting purposes. As additional applications, 
these membranes were also evaluated for their use in screening 
drug substances for pharmacological and toxicological 
23 
ef fects 62 - 66 • Success in these efforts led the companies to 
promote the cultured skins for their applications in assessing 
drug delivery67 • A question was raised if these membranes can 
in fact provide drug permeation information which is relevant 
to the human situation. A mechanistic study carried out by 
using model compounds indicated that the transport 
characteristics of the cultured membrane were not comparable 
to those of the human skin68 • The use of cultured skins in 
evaluating dermatological formulations is not a viable 
alternative. This is so due to the reasons given in an earlier 
section "Human In Vitro". As was stated earlier, in vitro 
models are not relevant to assessing local drug delivery. 
1. 3. 6. Synthetic Membranes: The only value of using synthetic 
membranes, e.g. SilasticR, cellulose acetate, polyurethane, 
etc. in the evaluation of transdermal and dermatological 
formulations is to understand/interpret data obtained from 
skin studies21 • 69 - 7 7 . Such mechanistic studies have been carried 
out to differentiate physicochemical and biological factors, 
which affect drug transport. Synthetic membranes are not meant 
to provide predictive information on the actual drug transport 
into or through the skin. Therefore, these membranes have only 
a limited value in the development of transdermal or 
dermatological products. 
1.4. Factors Which Affect Drug Delivery Into and Through the 
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An abundance of information exists in the literature on 
factors which affect drug delivery through the skin. Due to 
the emerging nature of transdermal products, many researchers 
have focused on the factors which affect drug flux across the 
skin. While these factors may not necessarily be relevant to 
drug delivery from dermatological products, they may provide 
some insight in as far as the barrier nature of the stratum 
corneum is concerned. The factors may be broadly divided into 
three categories viz. , physiological including hydration, age, 
gender or site; drug dependant including drug lipophilicity 
and drug solubility and concentration; and vehicle dependant 
effects. These factors will be discussed further. 
1.4.1. Physiological Factors: As mentioned earlier hydration 
or occlusion is probably the most notable of the factors 
studied37 ' 78 • It was long believed that hydration increased skin 
permeability of all drug substances78 - 81 • However, this was 
shown not to be the case via permeation studies with test 
permeants, n-alkanols 25 • 26 • In the hairless mouse and furry 
mouse models, it was shown that hydration did not affect the 
permeation of polar compounds. The transport of moderately 
polar/non-polar compounds increased substantially with 
hydration. The permeation of non-polar compounds actually 
decreased with hydration. Virtually no studies have been 
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reported on the effects of hydration on drug delivery to the 
skin layers from dermatological products. It is an important 
piece of information missing because it would appear that 
effects of hydration are equally or more important for 
dermatological drugs. Many dermatological vehicles and other 
formulation excipients cause hydration of the skin. Age, 
gender and site have also been reported as important factors 
which can affect the permeation and retention of drugs 82 . These 
effects may be compound related. Christopher and Kligman in 
1965, and Wildnauer and Kennedy in 1970 83 ·84 reported a lack of 
age-effects on the in vitro permeation of water in human 
skins. For fluorescein, however, a seven fold higher in vitro 
permeation was noted in older skins. In a study carried out 
using male and female hairless and furry mouse skins, and 
alkanols as test permeants, the age effects were studied over 
the entire age span of the animal 9 5 - 97 • It was found that the 
role of various pathways of drug permeation may change with 
the age of the skin. Notably, the follicular pathway was most 
affected in the first quarter of the age span. Gender is 
perhaps not a critical factor. Studies with alkanols in 
hairless and furry mice, and with propranolol in human skin, 
did not show substantial gender related changes84 ·86·88 . 
The site of application on the body has a substantial effect 
on the drug permeation42,0s,06,09,9o . Large site effects were 
reported by these workers. The primary cause of these effects 
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is morphological differences in the rate controlling layer, 
stratum corneum. The effects of age, gender and site on the 
local drug delivery have not been reported. 
1. 4. 2. Drug Dependant Factors: Drug lipophilicity can be 
expressed by partition coefficient and is probably the most 
important factor which affects drug permeation. Scheuplein and 
co-workers 91 studied this factor systematically with alkanols 
and found that permeation through the lipoidal pathways of 
human skin increased exponentially. A strong relationship was 
reported between drug permeation and octanol/water partition 
coefficients of several different drugs 77 • This partition 
dependence is due to the lipoidal nature of the physiological 
barriers. If this barrier layer is altered by either stripping 
of the cornified cells or other means, the effect of partition 
coefficient becomes less important21 • Partitioning of drug in 
the stratum corneum is also affected by formulation factors 
such as choice of vehicles, the type of dosage form, and 
particle size of the drug. Among these factors the vehicle 
effects is a very important factor. 
While majority of the studies reported pertain to drug 
permeation, some researchers have noticed a correlation 
between partition coefficients and therapeutic effects in 
topical drug delivery. For example, of 23 esters of 
betamethasone studied, the 17-valerate had the highest topical 
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activity 
activity 
which directly 
of the drug 
coeff icient 92 • 
correlates 
and the 
with the therapeutic 
lipid-water partition 
Drug solubility and concentration are also well studied 
factors for transdermal drugs. While there is rarely an 
exception to the dependence of flux on drug concentration, 
same argument cannot be made for drug solubility. 
Theoretically, drug permeation from saturated solutions would 
be highest because of the maximum thermodynamic activity of 
the drug. However, data reported on several drugs demonstrated 
that saturation flux was not dependent on drug 
solubility19 • 72 • 7 3 • 7 4 • This departure from the theoretical 
principles was attributed to the violation of following 
assumptions: 
a. Only the drug molecule will permeate into and through the 
skin. 
b. The skin will not be altered in any manner during the 
permeation process. 
c. The microenvironment in the skin layers will not be 
altered by the presence of drug and formulation 
excipients. 
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d. Drug concentration and therefore thermodynamic activity 
always remains constant in the formulation applied on the 
skin. 
The effects of drug solubility and concentration on drug 
retention are far less explored. No definite trend was 
observed between retention and solubility for two drugs, a PAF 
antagonist and a lipoxygenase inhibitor22 ' 23 . In these studies, 
effects of drug concentration on its retention in the 
epidermis and dermis were also examined. It was found that 
drug retention increased linearly with solubility in the 
epidermis while it increased asymptotically with solubility in 
the dermis. 
1.4.3 Vehicle Effects: Vehicle effects on the drug permeation 
have been extensively studied14 • 51 • 9 3 - 101 whereas only few reports 
exist on local drug delivery19 • 20 • 2 2 • 2 3 . Among the ones that were 
previously talked about, the following three factors affect 
the extent and the rate of drug permeation through the skin: 
vehicle, skin and drug. The first factor includes vehicle/skin 
partitioning, drug solubility, occlusive nature of 
formulations, drug concentration and pH of the formulation. 
Skin related factors include the skin itself, integrity of the 
barrier layer, skin hydration, vehicle retention in the skin 
and condition of the skin prior to formulation application. 
Irrespective of these two factors, the drug uptake into the 
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skin is changed because vehicles alter the barrier function of 
the stratum corneum. The skin related factors are known to be 
more critical than physicochemical factors 97 • 
Vehicle effects were evaluated by drug dissolved in a 
vehicle19 • 21 - 23 • 102 • 103 e.g. estradiol, PAF antagonist, lipoxygenase 
inhibitor, or mixed vehicle50 • 93 • 94 • 96 • 104 - 106 e.g. fluocinolone 
acetonide, fluocinonide, indomethacin, adenosine etc., or more 
sophisticated formulations, e.g. emulsions107 , gels108 - 110 , e.g. 
idoxuridine, tretinoin, etc, or ointments52 • 111 e.g. 
betamethasone derivatives etc., liposomal preparations109 • 112 , 
e.g. tretinoin, or niosomal preparations113 • 114 , microsponge 
systems115 , or polymeric microspheres116 • Most of these effects 
were studied in vitro and both lipophilic and hydrophilic 
drugs were used. The effects on drug deli very exerted by 
different vehicles and dosage forms varied a lot. 
One effect has been the topic of much research and interest, 
effect of vehicles on the state of hydration of the skin117 • In 
contrast to the above effect, vehicles which are immiscible 
with water and are lipoidal in nature, show an opposite effect 
on water loss from the skin and, therefore, on the state of 
hydration of the skin. Such vehicles reduce both insensible 
perspiration and the release of sweat. The sweat collects at 
the openings of the glands but, does not spread as a film 
between hydrophobic skin surf ace and hydrophobic vehicle 
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because the free surface energy of the vehicle-skin surface is 
smaller than that between water and the skin107 • For example if 
a lipophilic layer of a vehicle is present, it is not 
spontaneously replaced by the water-skin boundary layer if 
sweat is secreted1 05 • Lipophilic waxes and single phase 
vehicles such as isopropyl myristate possess approximately 
equal moisture occlusive properties in their resistance to 
moisture loss as does Saran Wrap Film105 • 118 - 121 • 
Mollgaard and Hoelgaard in 1983 97 conducted a thorough study 
to investigate the effects of 21 vehicles on the in vitro flux 
of estradiol from saturated solutions through excised human 
skin. These single vehicles ranged from commonly used 
vehicles, e.g. propylene glycol, PEG 400, glycerol to 
experimental vehicles, e.g. ethylene glycol, diethylene 
glycol, hexanetriol, decanol, etc, to controversial vehicles, 
e.g. dimethylsulfoxide. The flux results as shown in Table 2, 
showed a 220 fold . range, from 0.001 µg / hr/cm2 to 0.22 
µg/hr/cm2 . Lag times for the steady-state permeation were also 
provided. They ranged from zero hour for DMSO to 57 hours for 
triethylene glycol and triethanolamine. 
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Table 2. Ranking of Different Vehicles According to the 
( Flux of Estradiol 97 
# Vehicle Flux Lag Ranking 
(µ.g*cm- 2 Time 
*h-1) (hrs) 
1. Ethylene Glycol 0.22 13 1 
2. Propylene Glycol 0.12 18 2 
3. Dimethyl Sulfoxide 0.14 0 3 
4. Diethylene Glycol 0.12 53 4 
5. Propanediol(l,3) 0.11 39 5 
6. Triethylene Glycol 0.087 57 6 
7. Dipropylene Glycol 0.047 54 7 
8 . Glycerol 0.037 26 8 
9. Betahistine 0.028 8 9 
10. Methyl Salicylate 0.027 11 10 
11. Ethyl Oleate 0.025 14 11 
12. Diisoamylamine 0.019 12 12 
13. 2-amino-4- 0.018 11 13 
methylhexane 
14. Butanediol(l,4) 0.017 43 14 
15. Decanol(l) 0.014 18 15 
16. Triethanolamine 0.010 57 16 
17. Hexanetriol(l,2,6) 0.008 28 17 
18. Diethanolamine 0.007 5 18 
19. Pentanediol(l,5) 0.005 28 19 
20. PEG 400 0.001 - 20 
21. Tween 80 0.001 - 21 
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Transdermal and dermatological formulations typically contain 
more than one excipient. However, it is still useful to study 
skin uptake from single vehicles because it allows to choose 
appropriate vehicles for the final formulation. Some of the 
marketed dermatological products in fact contain large amounts 
of liquid vehicles . Examples include Retin-AR Lotion, SynalarR 
Lotion and TopicortR Lotion. For many of these products, the 
consistency (viscosity) is close to that of "neat" vehicles. 
A list of marketed products has been provided for the reader 
to get an idea of the type of vehicles typically used in 
dermatological formulations (see Table 3). 
DMSO is probably the most controversial and most studied 
vehicle in the transdermal and dermatological f ields123 - 121 • Soon 
after its use in therapeutic applications became known in mid 
1960s, DMSO became popular and widely used. However, an 
alarming report was issued by Huntington Research Center in 
England that DMSO can change the refractive index of the lens 
in the eyes of rabbits, pigs, and dogs. At that point, the FDA 
prohibited the therapeutic use of DMSO despite the fact that 
the new Huntington results contradicted its earlier 
conclusions as to the safety of DMSO. Extensive safety studies 
followed and it was concluded that no one had actually 
observed a single case of damage to the human eye due to 
DMS0128 and that DMSO is a very safe compound for human use 129 • 
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Table 3. List of Some of the 
Dermatological Products1 22 • 
Most Commonly Used Marketed 
# Drug, Strength Product Name Vehicle(s)* 
(Manufacturer) 
Indication : Abradant 
1. Urea Ureacin Lotion PG, MO 
(Pedinol) 
Indication : Acne 
1. Erythromycin, A/T/S Topical PG, Alcohol 
2% Solution(Hoechst) ( 6 6%) 
2. Benzoyl Benzac AC Water- Alcohol 
Peroxide, 21/2 I Base Gel (12%) 
5 and 10 % (Galderma) 
3. Erythromycin Benzamycin Topical Water, 
(3%) t Benzoyl Gel ( Dermik Labs) Alcohol 
Peroxide (5%) ( 16%) 
4. Benzoyl Brevoxyl Cleaning Water, PG 
Peroxide, 4% Lotion (Stiefel 
Labs) 
5. Clindamycin, Cleocin T Topical Gel: PEG 
2% Gel and Solution 400, PG, 
(Upjohn) water 
Solution: 
IPA ( 50 
%v/v), PG, 
water 
6. Tretinoin, Retin-A Liquid PG, 
(Ortho-MacNeill) Alcohol, 
water 
7. Erythromycin, Theramycin z PG, Alcohol 
2% Topical Solution (81% v/v) 
(Medicis) 
cont'd ... 
Table 3 (Cont'd) 
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Indication: Antibacterial 
1. Benzoyl Desquam-X Gel, Water, 
Peroxide, 2' 2 / 5, 10 (Westwood- Carbomer 
5, 10 % Squibb) 940 
2. Erythromycin, T-Stat 2 % Topical Alcohol 
2% Solution (71.2%) I PG 
(Westwood-Squibb) 
Indication : Antibiotics 
1. Clindamycin, Cleocin T Topical Gel: 
2% Gel and Solution PEG400, PG, 
(Upjohn) water 
Solution: 
IPA ( 5 0 
%v/v), PG 
2. Neomycin LazerSporin-C Water, PG 
Sulfate, Solution (Pedinol) 
Polymyxin B 
Sulfate and 
Hydrocortisone 
( 
1% 
Indication : Antiinflammatory Agents 
1. Podof ilox, Condylox Topical Alcohol 
0.5 % Solution ( 95%) 
(Oclasson) 
2 . Amcinonide, Cyclocort Topical Glycerin, 
0.1% Lotion (Fujisawa) IPM, PEG 
400 
3 . Betamethasone Diprolene Lotion Water, IPM, 
Dipropionate, (Schering) PG 
0.05% 
Cont'd ... 
Table 3 (Cont'd) 
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# Drug, Strength Product Name 
(Manufacturer) 
Indication : Dermatitis Relief 
1. Desonide, Desowen Lotion 
0.05% (Galderma) 
2 . Hydrocortisone Locoid Topical 
Butyrate, Solution 
0.1 % (Ferndale) 
3 . Hydrocortisone Hytone Lotion 
I 1, 21 / 2 % (Dermik Labs) 
Indication : Pruritis 
1. Amcinonide, Cyclocort Topical 
0.1% Lotion (Fujisawa) 
2. Floucinolone Synalar Topical 
Acetonide, Solution (Syntex) 
0.1% 
3. Clobetasol Temovate Scalp 
Propionate, Application 
0.05% (Glaxo) 
Indication : Psoriasis 
1. Betamethasone Diprolene Lotion 
Dipropionate, (Schering) 
0.05% 
Indication : Hair Growth 
1. Minoxidil, 2% Rogaine, For 
Topical Use 
(Upjohn) 
*PG 
IPM 
IPA 
MO 
Propylene Glycol 
Isopropyl Myristate 
Isopropanol 
Mineral Oil 
Vehicle(s) 
MO, PG 
IPA ( 50%) f 
Glycerin 
PG, water 
Glycerin, 
IPM, PEG 
400, water 
PG,water 
IPA 
(39.3%) f 
water 
Water, IPM, 
PG 
PG, 
Alcohol, 
water 
Comment: Note that the products may contain additional 
excipients . Only those excipients mentioned in the PDR are 
reported here. 
36 
{ 
I 
The effect of DMSO on the skin uptake of drugs is dependent on 
its concentration in the vehicle. Small increases were 
observed upto 
50 % concentration in water. Above 50 %, the effect increases 
exponentially130 - 135 . 
Propylene glycol and ethanol are also extensively studied 
vehicles 52 • 79 • 93 • 95 • 117 • 13 6 - 142 • It is noteworthy to mention these two 
vehicles together because they have been used in several 
marketed products including Retin-AR Lotion, Ureacin Lotion, 
Cleocin-T lotion and RogaineR Topical Solution. The 
combination vehicle was used in these products apparently 
because it provided an optimal drug efficacy. It is not clear 
if this combination vehicle provided an optimal topical drug 
delivery (retention) too. 
Additional studies have appeared in the literature on the 
permeation enhancing effects of these vehicles when used 
separately. Turi in 197914 3 showed that the permeation of 
diflurasone diacetate was enhanced by propylene glycol. The 
enhancement was observed to be proportional to propylene 
glycol concentration in the formulation. Propylene glycol was 
found to be effective in increasing the flux of f luorouracil144 
and hydrocortisone145 • 
The enhancing effects of ethanol on drug permeation have also 
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been extensively studied146 • At least two transdermal products 
on the market, EstradermR 122 • 147 - 149 and DuragesicR 1 5 0 contain 
ethanol as a major component. From mechanistic standpoint, 
ethanol is probably the most invest i gated vehicle for its 
effects on drug permeation. Many researchers generally believe 
that the increased skin permeability results from denaturation 
or conformational changes in the keratin of the stratum 
corneum151 - 154 • Under appropriate conditions, some hydrogen-
bonding sol vents, e.g. DMSO, ethanol, DMF, methanol, and 
propanol can open-up the stratum corneum cells and thus 
increase the diffusivity of many compounds 1 35 • 154 - 157 • Some 
investigators believe that "increased lipid-phase fluidity" is 
related to the increased permeability of the skin 156 - 161 • These 
researchers confirmed their speculations and beliefs by 
conducting differential Scanning Calorimetric, Infrared 
Spectrometry and Fourier Transform Infrared experiments. 
It has been suggested that alcohol enhances drug partition 
into the stratum corneum which then results in enhanced drug 
permeation146 • 1 62 - 1 66 • These studies were conducted on several 
compounds which included nicardipine. nitroglycerin, estradiol 
and an unidentifiable ionizable compound. Some common 
observations were made on these reports by Yum, et al . in 
1994 1 46 and are interpreted as follows: 
a. Drug solubility appeared to be an exponential function of 
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ethanol concentration in the vehicle. This point 
,however, may not apply to all drugs and may very well be 
a function of the composition of the vehicle. 
b. Transdermal flux of the drugs tested appeared to be an 
exponential function of ethanol concentration. Again, 
this relationship may not hold true for a l l drugs. The 
other components in the vehicle as well as the inherent 
properties of the drug itself can greatly influence the 
flux vs ethanol concentration. 
c. The enhanced flux across the epidermis or stratum corneum 
appeared to be directly proportional to drug 
concentration in the tissue which in turn increased with 
increasing ethanol concentration. This observation should 
be taken with a word of caution. Flux experiments for 
transdermal drugs are normally done under infinite dose 
conditions and the conclusions may not necessarily apply 
to the finite dose situations which prevail for 
dermatological drugs. Besides, if the drug concentration 
in the tissue is determined only at the end of a flux 
experiment, the observed relationship pertains only to 
steady-state transport situation. 
AzoneR (l-dodecylazacycloheptan-2-one) is another extensively 
studied vehicle, although it is better known as an 
enhancer31 ' 1 67 - 173 • Numerous reports have appeared in the 
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literature on the effects of AzoneR on the permeation of 
various compounds 174 - 182 • Many of these drugs are listed in Table 
4. Both types of studies, screening of drugs for assessing 
transdermal feasibility as well as mechanistic aspects have 
been carried out. It was found that solute delivery typically 
increased with Azone concentration31 contradicting some 
researchers belief that enhancement of permeation is a 
saturable process with a maximal enhancement associated with 
a particular optimal concentration of Azone 167 • 174 Vehicle 
selection plays an important role31 in: 
a. Whether or not the enhancement effects will plateau. 
b. Producing a maximal AzoneR concentration beyond which 
permeation will actually decline. 
In spite of the extensive evaluation of Azone, it is not 
apparent that it will find its place in any marketed product. 
It is so because it does not provide any unique properties 
with regard to drug delivery. 
Acetone has been used by many researchers to evaluate 
transdermal and dermatological drugs 183 • 184 • Guinea pig was used 
as an animal model for human skin absorption of 
hydrocortisone, testosterone and benzoic acid by studying 
permeation from acetone solutions185 • The enhancing effect of 
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acetone on the permeation of water through murine skin was 
compared with that of DMSO, chloroform, ethanol and ether186 • 
The enhancing effects of these four vehicles were found to 
follow the following rank order: Chloroform > ether > DMSO > 
acetone > ethanol. Several other compounds have been studied 
by using acetone as a vehicle155 • 187 • According to them, acetone 
readily evaporates from the skin surf ace leaving behind a 
11 solid penetrant 11 from which drug permeation or retention 
occurs. Many laboratories routinely utilize 
vehicle of choice to evaluate new drug 
pharmacological effects in in vitro and in 
acetone as a 
compounds for 
vivo models. 
Whether or not acetone is a suitable vehicle for such purposes 
is a topic for on-going debate 1 • 2 • 
Isopropyl myristate has been found to be an effective vehicle 
for many drugs. The permeation of fluocinolone acetonide and 
its acetate through human skin increased when isopropyl 
myristate was used in combination with volatile vehicle, 
isopropanol 104 • Smaller increases were noted when the volatile 
vehicle component was not allowed to evaporate, i.e. when the 
site of application was occluded. The permeation of acyclovir 
through hairless mouse skin was studied using vehicles 
including isopropyl myristate57 • In this case the enhancer, 1-
farnesylazacycloheptan-2-one (7 FU), 1-geranylazacyclovir-2-
one (7 GU), 1-geranylazacyclopentan-2-one (5 GU) and Azone, 
were not found to be effective when used in isopropyl 
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myristate vehicle. It was reasoned that the enhancers and the 
vehicle were too similar to each other with respect to the 
physico-chemical properties. Pretreatment of the skin with 
some vehicles including isopropyl myristate, increased the 
permeability of the skin for compounds studied later158 • It is 
likely that the pretreatment allowed the vehicle to permeate 
into the skin and be 
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Table 4. Drugs 
Enhancement 31 • 181 • 
That 
I # I Class 
1. Antibiotics 
2. Anti fungals 
3. Antivirals 
4. Anthelmintics 
5. Antimetabolites 
6. Depigmenting 
Agents 
7. Corticosteroids 
8. Nonsteroidal 
Antiinf lammator 
y Drugs 
9. Narcotic 
Antagonist 
10. Cardiovasculars 
11. Alkaloids 
12. Sympathomimetic 
s 
13. Benzodiazepines 
I 
Exhibit Azone-Induced Permeation 
Compound I 
Clindamycin Phosphate 
Erythromycin base 
Erythromycin 
Metronidazole 
Griseofulvin 
Cytarabin 
Idoxuridine 
Thiabendazole 
5-Fluorouracil 
Hydroquinone 
Amcinonide 
Triamcinolone Acetonide 
Ibuprofen 
Indomethacin 
Naloxone 
Amlodipine 
Isosorbide Dinitrate 
Morphine 
Isoproterenol 
Midazolam Maleate 
Diazepam 
43 
( 
retained there. The drugs soluble 
retained in the skin will have 
in the vehicle component 
a better chance to be 
transported across the skin. With time, the vehicles 
themselves will be getting into the skin and therefore 
creating and maintaining a new microenvironment which is more 
favorable to these drugs studied. Was hi take, M, et al. 189 
investigated the in vitro permeation and retention of 
salicylic acid and carbinoxamine from four oily vehicles 
including isopropyl myristate. The vehicles which had better 
affinity for the drug, provided a lower skin permeation. Using 
neat vehicles, the enhancing effects of four vehicles on the 
limiting flux (flux from saturated solutions) through hairless 
mouse skin ranked: isopropyl myristate > propylene glycol > 
medium chain triglyceride > polyethylene glycol 400 > water > 
mineral oil for Ro 10-167072 • The rank order for Ro 15-1570 
was: medium chain triglyceride > isopropyl myristate > 
polyethylene glycol 400 >mineral oil 73 • For another compound, 
isotretinoic acid in excised human skin, the rank order of the 
vehicles tested was isopropyl myristate > medium chain 
triglyceride > polyethylene glycol 400 > 
ethanol/water/ (polyethylene glycol 400) mixture74 • For the 
three drugs tested, no definite relationship between the 
limiting flux and drug solubility was observed. These studies 
only stress the fact that vehicle effects on drug 
permeation/retention are complicated and for most part are 
dependent upon the specific drugs used. 
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Polyethylene glycol 400 is also a commonly used vehicle in 
dermatological formulations. Generally, this vehicle is 
regarded as an inefficient vehic l e to provide optimal 
permeation/retention of drugs when used by itself22 · 23 · 73 . 
Permeation of four retinoids was studied from five vehicles 
using excised monkey skin82 • The results indicated that the 
permeation followed rank order: propylene glycol isopropyl 
alcohol > mineral oil > diisopropyl adipate > polyethylene 
glycol 400. PEG 400 was found to be at the bottom of the 
vehicles studied for the permeation of Ro 23-3544 through 
excised skin of hairless guinea pigs19 • 
Most of the vehicle effects mentioned are on the transdermal 
drugs. The effects of vehicles on topical drug delivery to the 
skin layers are not well studied and understood. Some of the 
recent studies, using both in vitro and in vivo animal skin 
models, have shown that vehicle effects on the local drug 
delivery are also dramatic and depend on the drugs used. The 
in vitro retention of Ro 23-3544 in hairless guinea pig skin 
was noted to vary by orders of magnitude for ten vehicles 
studied1 9 • Vehicles ranked differently for the permeation data 
than for the retention data. Large vehicle effects were also 
observed on the in vivo epidermal/dermal retention of Ro 24-
5413 22 and Ro 24-0238 23 from many vehicles studied. 
Vehicle effects on topical drug delivery have also been 
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studied using the tape stripping technique. Influence of 17 
simple vehicles including combinations of ethanol, water, 
ethylene glycol and triton X-100 were studied using hairless 
rat. The stratum corneum reservoir was assessed. It was found 
that the total amount of the drug that penetrated over four 
days varied by a factor of 50, thus demonstrating the 
importance of vehicle in skin absorption29 • 54 • 55 • Pershing190 
investigated whether the stripping method could also predict 
the pharmacological effect of a drug. They showed that the 
total amount of betamethasone dipropionate in the tape 
stripped from human skin correlated with the vasoconstriction 
in vivo. A new penetration enhancer, HPE-101 increased the 
permeation of indomethacin through tape stripped guinea pig 
skin1 9 1 • Some researchers have studied the retention of drugs 
in the skin after carrying out a flux study. The topical 
penetration of piroxicam was measured after an in vitro flux 
study through pig skin. It was concluded that the topical 
penetration of the drug is dependent on the distribution of 
local cutaneous vasculature1 92 • 
Vehicle effects on drug retention are actually critically 
important for dermatological drugs but, unfortunately not much 
work has been done in this area. The awareness, however, has 
increased in the recent few years and it is hoped that a lot 
more will be learnt about local drug delivery and its 
optimization via a judicial selection of vehicles. 
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2.0 OBJECTIVES 
The objectives of the present study were as follows: 
1. To determine solubility of two model drugs, 
hydrocortisone (HC) and triamcinolone acetonide (TAC) , in 
a wide variety of vehicles which are either used in 
topical drug delivery systems or are potential vehicles. 
2. To study the effects of these vehicles on the in vivo 
retention of HC and TAC in the epidermis and dermis of 
hairless rat. 
3. To draw interpretations from the observed data with 
respect to vehicle effects on the in vivo drug retention, 
drug retention vs solubility, and drug retention vs 
lipophilicity. 
4. Since corticosteroids are poorly absorbed in the skin the 
results of this study are expected to aid in optimizing 
the selection of vehicles for topical drug delivery and 
in the better selection of vehicles for these two 
corticosteroids. 
5. To further explore the in vivo hairless rodent model in 
screening potential dermatological formulations for local 
drug delivery as a step prior to clinical studies. 
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EXPERIMENTAL 
3.1. Materials 
3.1.1. Animals: 
Male Hairless Rat (Strain: CD Hairless) was used as the animal 
model and animals of 8-12 weeks age were obtained from Charles 
Rivers Laboratories, Massachusetts. The animals were housed in 
a suitable facility and the environmental conditions were 
controlled. The animals had access to food and water ad lib. 
3.1.2. Model Drugs: 
Two glucocorticoids, hydrocortisone (HC) and triamcinolone 
acetonide (TAC) were chosen as model drugs. These two drugs 
have substantially varying ether/water partition coefficients, 
1.3 for HC and 13.1 for TAC. The reported water solubility for 
hydrocortisone is 0.28 mg/mL and that for TAC is less than 0.1 
mg/mL. The formulations of these drugs were "spiked" with 
their 3H-labeled forms. The labelled and unlabelled drug 
compounds were obtained from the following sources: 
Hydrocortisone Sigma Chem. Co., St. 
Louis, MO. 
Triamcinolone acetonide Sigma Chem. Co., St. 
Louis, MO. 
Hydrocortisone3H ICN Biomedical Co . , 
Irvine, CA. 
Triamcinolone acetonide3H ICN Biomedical Co., 
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Irvine, CA. 
3 .1. 3. Chemicals and Materials: The chemicals and materials 
used and 
their sources are as follows: 
Acetonitrile, HPLC Grade 
Acetone, HPLC Grade 
Water, HPLC Grade 
Tritium Cocktail 
Sodium Pentobarbital 
Xylazine 
Ketamine 
Oxygen 
Nitrogen 
Carbon Dioxide 
Alcohol Swabs 
Fisher Sci. Co ., Fair Lawn, NJ. 
Fisher Sci. Co . , Fair Lawn, NJ. 
Hoffmann-La Roche Inc., Nutley, NJ. 
R . J. Harvey Inst., Co . , Paramus, NJ. 
Sigma Chem. Co.,St. Louis, MO. 
Mobay Corp . , New York, NY. 
Fort Dodge Labs Inc.,Fort Dodge, IO. 
JWS Technologies, Piscataway, NJ . 
Liquid Carbonic Inc.,Oak Brook, IL. 
Liquid Carbonic Inc ., Oak Brook, IL. 
Becton Dickinson, Inc . ,Franklin Lakes, 
NJ. 
3 .1. 4. Vehicles: The vehicles that were studied in this 
project are listed below along with their sources. 
Ethylene Glycol 
Diethylene Glycol 
Propylene glycol 
PEG 200 
PEG 300 
PEG 400 
Ethanol 
Isopropanol 
Isostearyl Alcohol 
Isopropyl Myristate 
Isopropyl Palmitate 
Miglyol 812R 
Miglyol 840R 
Imwitor 408R 
Imwitor 412R 
Dimethyl Sulf oxide 
AzoneR 
TranscutolR 
Linoleic Acid 
Oleic Acid 
Monoacetin 
Diacetin 
Triacetin 
Dow Corning Co., Midland, MI. 
Dow Corning Co., Midland, MI. 
Sigma Chem. Co., St. Louis, MO . 
BASF Chem . , Washington, NJ. 
BASF Chem . , Washington, NJ. 
BASF Chem., Washington, NJ. 
Sigma Chem . Co . , St . Louis, MO. 
Fisher Sci. Co.,Fair Lawn, NJ. 
Fisher Sci. Co . ,Fair Lawn, NJ . 
Unichema Chem., Chicago, IL. 
Unichema Chem., Chicago, IL. 
Huls Amer. Inc.,Piscataway, 
Huls Amer. Inc.,Piscataway, 
Huls Amer. Inc.,Piscataway, 
Huls Amer. Inc.,Piscataway, 
NJ. 
NJ. 
NJ. 
NJ . 
Sigma Chem . Co., St . Louis, MO. 
Nelson Research, Irvine, CA. 
Gattefosse, Inc . ,St . Priest, France 
Sigma Chem. Co., St . Louis, MO . 
Fisher Sci. Co.,Fair Lawn, NJ. 
Unichema Chem.,Chicago, IL . 
Unichema Chem.,Chicago, IL. 
Unichema Chem.,Chicago, IL . 
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Tributyrin 
Tricaprylin 
Triolein 
3.2. Methods 
Sigma Chem. Co.,St. Louis, MO. 
Sigma Chem. Co . ,St. Louis, MO. 
Sigma Chem. Co ., St. Louis, MO. 
3.2.1. Radioisotopic Analysis: Liquid Scintillation Counter 
LSC 9800, Beckman Instruments Co., and a specialized Tritium 
Cocktail, R. J. Harvey Instruments Co., Paramus, NJ, were used 
for the analysis of 3H- labeled HC and TAC. 
3.2.2. Determination of Solubility of HC and TAC in Various 
Vehicles: Solubility of HC and TAC was measured in the 
vehicles listed in 3.1.4. An excess amount of the drug was 
suspended in a measured amount of vehicle. The suspension was 
shaken at 37°C for 72 hours and was filtered into a preheated 
vial (37°C) by using a 5 mL syringe and a 0.45 µ filter which 
were also preheated at 37°C. The filtrate was diluted and 
assayed by HPLC as reported by Tymes, N. J., in 1977193 • This 
method was capable of analyzing both, HC and TAC. The details 
of the HPLC instrument and experimental conditions used are 
provided in Table 5. 
Standard Solutions were prepared by dissolving 15 mg of HC in 
15 mL of acetonitrile and 15 mg of TAC in 15 mL of acetone to 
obtain a concentration of 1 mg/mL. The Precision of injections 
was checked by making four 10 µL injections of the Standard 
Solutions of HC and TAC. The percent relative standard 
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deviation of the area under the curve for both the drugs was 
below 2 % indicating satisfactory precision. 
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Table 5. Instrumentation and Experimental Conditions For HPLC 
Analysis of Hydrocortisone and Triamcinolone Acetonide. 
# Experimental Description 
Conditions 
1. Pump Waters Model 600E, Multisolvent 
Delivery System 
2. Injector Waters WISP 712B Auto Sampler 
Injector 
3. Detector ABI Programmable Wavelength Detector 
4. Column Microbondapak C1a / 30 cm, 4 mm i.d. 
5. Mobile Phase Acetonitrile:Water (40: 60) 
6 . Flow Rate 1. 5 mL/min 
7. Injection 10 µL 
Volume 
8. Retention Hydrocortisone 
-
4.0 min 
Time Triamcinolone Acetonide 
-
6.0 min 
9 . Run Time 10 Minutes 
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The linearity of detection of HC and TAC was determined by 
serially diluting the Standard Solution (1 mg/mL) with 
acetonitrile for HC and with acetone for TAC. The dilutions 
were performed to obtain a concentration range of 1 µg/mL to 
1 mg/mL. Plots of peak areas versus concentrations (Figures 4 
and 5) showed linear responses with correlation coefficients 
over 0.999. 
3.2.3. In Vivo Retention Procedures: The following 
experimental procedures were used to determine the in vivo 
retention of HC and TAC: 
a. Preparation of Formulations: 3H labelled HC and TAC 
solutions (lµCi/µL) were received from ICN Biomedicals, 
Irvine, CA, in 200 proof ethanol. The specific activity 
of HC was 56 Ci/mM and that of TAC was 49.5 Ci/mM. Fifty 
µL of the solution was diluted to one mL using 200 proof 
ethanol to obtain a concentration of 0.05 µCi/µL. Fifty 
four µL of this stock solution was pipetted in a vial and 
alcohol was evaporated under a constant flow of nitrogen 
to get an eventual count of about 30,000 dpm/µL ("Hot" 
Residue) . Calculations indicated that this level of 
radioactivity was sufficient for radioisotopic analysis. 
"Cold" solution of each drug was prepared in each vehicle 
at half of drug solubility to maintain a constant 
53 
\ 
thermodynamic activity22 • 23 • 97 • Two hundred µL of this 
solution was added to the "hot" Residue. This mixture 
was sonicated for five minutes to ensure a uniform mixing 
of the 11 hot 11 and the 11 cold 11 forms of the drugs. The 
uniformity of mixing was checked by counting the 
radioactivity of three five µL aliquots of the mixture. 
b. Preparation of Animals: Male hairless rats of age 8-12 
weeks were preanesthetized by using a mixture of oxygen 
and carbon dioxide. The rats were anesthetized by 
injecting a mixture of ketamine (100 mg/Kg) and xylazine 
(10 mg/Kg) subcutaneously . Additional injections were 
made if needed. The abdominal region of the animals was 
washed with water to remove debris and a circular 10 cm2 
area was marked. The animals were laid on a heating pad 
against their backs. 
c. Formulation Application: Twenty µL of the drug 
formulation was applied on the 10 cm2 marked area (2 
µL/cm 2 ) on the abdomen of the animal by using a glass 
rod. The formulation was gently spread and rubbed on the 
skin. Experiments were carried out under ambient 
conditions. 
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d. Excision of Skin: At the end of the experiment i.e. 
three hours, the animals were sacrificed by an 
intracardiac injection of pentobarbi tal ( 12 0 mg /mL) , 
Sigma Chemical Co., St. Louis, MO. Excess formulation was 
removed by carrying out a "topwash" procedure. This was 
done by wiping the skin four times with each of six 
alcohol swabs used. The marked area of the skin was 
excised using a #21 scalpel and a forcep, and was placed 
in a petridish. 
e. Sectioning of Skin Layers: The petridish containing the 
skin was microwaved for four seconds and the skin was 
sectioned into epidermis and dermis 194 • The epidermal and 
dermal layers were weighed and placed in scintillation 
vials. 
f. Measurement of the Radioactivity in Skin Samples: The 
radioactivity was measured by oxidizing the skin layers 
in a RX-500 Biological Oxidizer, R. J. Harvey 
Instruments, Paramus, NJ. The oxidizer consisted of a 
combustion chamber which was under a constant flow of 
nitrogen and was maintained at 900°C. During the 
combustion, nitrogen was replaced with oxygen. The 
combustion was completed within four minutes. The skin 
layers were oxidized and tritium was captured as 
tri tiated water in the scintillation fluid. The 
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scintillation vials were placed in an LSC 9800 and the 
( radioactivity of the oxidized skin layers was determined. 
3.3. Data Analysis: The observed radioactivity was converted 
into drug concentration in terms of drug amount by using the 
specific activity of the formulation. Drug concentration in 
skin layers was calculated by dividing the amount observed by 
the weight of the tissue. This was expressed in terms of 
µg/Gm. The data was also expressed as percent of the applied 
dose retained in the skin layer and was calculated as follows: 
% R = D x Wt. x 100 
Dose 
where %R = Percent of dose retained 
D = Drug in µg/gm 
Dl= Dose Applied 
Wt= Tissue weight in gm 
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4.0. RESULTS AND DISCUSSION: 
4.1. High Performance Liquid Chromatography (HPLC) Method 
An HPLC method was used to determine the solubility of HC and 
TAC. This method has been reported in the literature (Table 5) 
for the analysis of several corticosteroids. A lack of 
interference by 26 vehicles used in the present study with the 
method was established. 
4.2. Solubility of HC and TAC in Vehicles Studied 
Table 6 contains data on the solubility of HC and TAC in the 
vehicles tested. The vehicles belonged to the class of 
glycols, polyethylene glycols, alcohols, esters, glycerides, 
mixed commercial vehicles and conventional enhancers. 
Generally, the trends in the solubility within each class of 
vehicles was similar for the two drugs tested. The solubility 
values for a given drug in a given class of vehicles, show 
substantial ranges. Overall, the solubility of HC ranged from 
0.15 mg/mL to 286.8 mg/mL, a 1912 fold range for all vehicles 
tested. These values for TAC ranged from 0.14 mg/mL to 321.7 
mg/mL, a range of 2297 fold. 
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Table 6. Solubility of Hydrocortisone (HC) and Triamcinolone 
Acetonide (TAC) in the Vehicles Tested. 
I 
# 
I 
VEHICLES 
I 
SOLUBILITY (mg/mL) 
I HC I TAC 
1. Ethylene Glycol 12.4 4.6 
2. Di ethylene Glycol 25.2 15.9 
3. Propylene Glycol 12.0 12.1 
4. PEG 200 23.9 17.8 
5. PEG 300 17.3 15.5 
6. PEG 400 12.8 13.1 
7. Ethanol 10.1 23.2 
8. Isopropanol 4.46 3.40 
9. Isostearyl Alcohol 1.14 1. 20 
10. Isopropyl Myristate 0.320 0.190 
11. Isopropyl Palrnitate 0.180 0.140 
12. Monoacetin 12.2 16.7 
13. Diacetin 17.3 15.1 
14. Triacetin 4.00 3.80 
15. Tributyrin 0.250 0.190 
16. Triolein 0.230 0.220 
17. Tricaprylin 2.14 0.610 
18. Imwitor 408R 8.30 7.90 
19. Irnwitor 412R 22.3 1. 90 
20. Miglyol 812R 0.420 0.490 
21. Miglyol 840R 0.900 0.700 
22. Oleic Acid 0.150 0.190 
23. Linoleic Acid 12.2 0.27 
24. TranscutolR 23.8 13 .3 
25. Dimethyl Sulfoxide 286.8 321.7 
26. AzoneR 46.4 46.7 
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4.3. In Vivo Retention Studies 
4.3.1. Effects of Vehicles: Details of the epidermal and 
dermal retention values for all the vehicles are given in the 
appendix A and B. Tables A. l. - A. 26. and B .1. - B. 26. contain 
data on the in vivo retention of HC and TAC for all the 
vehicles studied, respectively. Each table contains actual 
data obtained for the epidermis and dermis. Three animals were 
used for each experiment. Average retention values along with 
the respective standard deviations are tabulated. 
Summaries of the in vivo skin retention of HC and TAC are 
presented in Tables 7 and 8, respectively. These data were 
arranged according to the vehicle class used. Within each 
class, data were ranked in the descending order of average 
percent of dose retained in the epidermis. The ranges within 
each group were calculated by dividing the highest retention 
by the lowest retention. Among the glycols, the epidermal and 
dermal retention ranges were almost similar for HC. A six 
fold range for epidermal and a nine fold range for dermal 
retention was observed for TAC. Interestingly propylene 
glycol ranked as the best vehicle for epidermal retention for 
both HC and TAC. The ranking of the epidermal and dermal 
retention was different for both HC and TAC. 
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Table 7 . Ranking of Vehicles Classwise, According to the 
Percent of Dose of Hydrocortisone Retained in the Hairless Rat 
Skin Layers . 
# VEHI CLES PERCENT RETAINED ± S.D . 
EP I DERMI S DERMIS 
1 . Propylene Glycol 4.75 ± 0.856 1.15 ± 0.533 
2. Ethylene Glycol 3.60 ± 1.97 1.09 ± 0.425 
3. Diethylene Glycol 2.80 ± 0.508 1. 32 ± 0.317 
4. PEG 300 0.145 ± 0 .119 0.0843 ± 0.0186 
5. PEG 200 0.106 ± 0.02 0. 0613 ± 0.00808 
6. PEG 400 0.043 ± 0.0295 0.0570 ± 0.00346 
7. Isostearyl Alcohol 2.78 ± 0.320 3.82 ± 1.90 
8. Ethanol 1. 36 ± 0.395 0.230 ± 0.0857 
9. Isopropanol 1. 27 ± 0.302 0 . 142 ± 0.0305 
10. Isopropyl 1.73 ± 0.534 2.24 ± 0.320 
Palmitate 
11. Isopropyl 1. 71 ± 0 . 847 1.58 ± 0.225 
Myristate 
12. Tributyrin 1.63 ± 0.391 0.779 ± 0 . 220 
13. Tricaprylin 1. 03 ± 0.124 1.13 ± 0 . 154 
14. Triolein 0.646 ± 0.179 0.258 ± 0.0311 
15 . Monoacetin 0.621 ± 0 .116 0.319 ± 0.159 
16. Diacetin 0.145 ± 0.00165 0.198 ± 0 . 0991 
17 . Triacetin 0.129 ± 0.0323 0 .137 ± 0.0578 
18. Miglyol 812R 3.52 ± 1. 02 1. 99 ± 0.652 
19. Miglyol 840R 2.41 ± 0.226 3.06 ± 0.398 
20. Imwitor 408R 3.56 ± 1. 67 2.53 ± 0.459 
21. Imwitor 412R 1. 52 ± 0. 511 1.17 ± 0 .136 
22. Dimethyl Sulfoxide 3.60 ± 1. 03 0.838 ± 0.483 
23. Oleic Acid 1. 55 ± 0.249 1.84 ± 0.150 
24. AzoneR 0 . 970 ± 0.260 1 . 40 ± 0.0709 
25. Linoleic Acid 0.815 ± 0.617 1. 60 ± 0.542 
26. Transcutol R 0.567 ± 0.141 0.640 ± 0.100 
Rank A: Ranking of Vehicles by \ of Dose Retained in Epidermis 
Rank B: Ranking by Vehicles by \ of Dose Retained in Dermis 
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RANK 
A B 
1 2 
2 3 
3 1 
4 4 
5 5 
6 6 
1 1 
2 2 
3 3 
1 1 
2 2 
1 2 
2 1 
3 4 
4 3 
5 5 
6 6 
1 3 
2 1 
3 2 
4 4 
1 4 
2 1 
3 3 
4 2 
5 5 
Table 8. Ranking of Vehicles Classwise , According to the 
Percent of Dos e of Triamcinolone Acetonide Ret a ined in the 
Ha irless Rat Skin Layers. 
# ' s VEHI CLES PERCENT RETAINED ± S . D. RANK 
EPIDERMIS DERMIS A B 
1 Propylene 5.09 ± 1. 47 0 . 769 ± 0.422 1 2 
Glycol 
2. Ethylene Glycol 4.41 ± 1. 37 1.61 ± 1.09 2 1 
3. Diethylene 0.857 ± 0.246 0.182 ± 0.0767 3 3 
Glycol 
4. PEG 200 0 . 110 ± 0.0437 0.0707 ± 0.0422 4 4 
5 . PEG 300 0.0423 ± 0.0150 0.0463 ± 0.00850 5 6 
6. PEG 400 0. 011 ± 0.000954 0.0473 ± 0.00451 6 5 
7. Isopropanol 0.885 ± 0.417 0.172 ± 0.0359 1 3 
8. Ethanol 0.755 ± 0.273 0. 311 ± 0.0945 2 2 
9. Isostearyl 0.452 ± 0.156 0.721 ± 0 . 206 3 1 
Alcohol 
10. Isopropyl 1. 92 ± 0.249 3. 71 ± 2.80 1 1 
Palmitate 
11. Isopropyl 1. 84 ± 0.526 1.89 ± 0 . 131 2 2 
Myristate 
12. Triolein 2.18 ± 1.32 0.809 ± 0 . 268 1 2 
13. Tributyrin 1.64 ± 0.442 1. 09 ± 0 . 107 2 1 
14. Tricaprylin 1.62 ± 0.0961 0.699 ± 0 . 0862 3 3 
15. Monoacetin 0 . 640 ± 0.532 0.203 ± 0.0777 4 4 
16. Triacetin 0.157 ± 0.0661 0.196 ± 0 . 0480 5 5 
17 . Diacetin 0.0643 ± 0.0240 0.0440 ± 0.0137 6 6 
18. Miglyol 840R 2 . 44 ± 0 . 373 2.98 ± 0.255 1 1 
19. Miglyol 812R 1.07 ± 0.302 1. 56 ± 0.589 3 4 
20. Imwitor 40 8R 1. 85 ± 0.762 2.50 ± 0.709 2 2 
21. I mwitor 412R 0.975 ± 0.370 1. 84 ± 0.272 4 3 
22. Dimethyl 2.21 ± 0.622 0.525 ± 0.10 3 1 5 
Sulfoxi de 
23. Transcutol R 1. 06 ± 0.267 0.614 ± 0.190 2 4 
24. AzoneR 0.967 ± 0.216 1.12 ± 0.144 3 3 
25 . Linoleic Acid 0.898 ± 0.0835 1 . 66 ± 0 . 441 4 2 
26 . Oleic Acid 0.682 ± 0.214 1.77 ± 0. 514 5 1 
Rank A: Ranking of Vehicles bi \ ~ or Dose Retainea in E y p idermis 
Rank B: Ranking by Vehicles by \ of Dose Retained in Dermis 
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For the polyglycol vehicles, a range of five fold for 
epidermal and a 1.5 fold dermal retention was observed in the 
case of HC while a 10 fold range for the epidermal and a 1.5 
fold range for the dermal retention was observed for TAC. PEG 
400 provided the lowest epidermal and dermal retention of HC 
and TAC. Similar findings have been reported for other drugs 
such as a PAF Antagonist and a lipoxygenase inhibitor19 • 22 • 23 • 
Reasons for such a lack of drug delivery capability of PEG 400 
are not clear. In spite of such property of PEG 400 it is 
still widely used in dermatological formulations. 
The results obtained with the three alcohols tested are of 
interest. Ethanol and isopropanol showed comparable epidermal 
retention of HC. The epidermal retention values of HC obtained 
I 
with isostearyl alcohol were about twice as high as with 
ethanol or isopropanol. The dermal retention values for HC 
obtained with isostearyl alcohol were over 15-20 fold higher 
than those obtained with ethanol and isopropanol. The dermal 
retention of HC from isostearyl alcohol was substantially 
higher than that from either ethanol (16.6 fold higher) or 
from isopropanol (26.9 fold higher). These interesting data 
suggest that isostearyl alcohol is a much superior vehicle for 
HC than TAC because of the substantially higher epidermal and 
dermal retention values obtained, 6 fold higher epidermal and 
5 fold higher dermal retention values. TAC showed comparable 
epidermal and dermal retention, however, the epidermal 
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retention values for TAC with isostearyl alcohol were about 
half of those obtained with ethanol and isopropanol. The 
dermal retention of TAC doubled in going from isopropanol to 
ethanol and doubled further from isostearyl alcohol. 
The two esters evaluated, isopropyl palmitate and isopropyl 
myristate provided comparable epidermal retention for both HC 
and TAC. The dermal retention observed with palmitate was 
about 1.4 fold higher than with myristate for HC and about 2 
fold higher for TAC. In general, both esters appear to be good 
vehicles for the two drugs investigated. 
The epidermal and dermal retention values of HC and TAC 
obtained with the six glyceride vehicles studied are generally 
lower than those seen with the vehicles discussed thus far. 
Ranges of 13 fold epidermal and 8 fold dermal retention were 
noted for HC. These ranges for TAC were substantially 
different, 34 fold for the epidermal and 25 fold for the 
dermal retention. Generally, for a given vehicle tested, 
higher retention was observed for TAC than for HC. Overall, it 
appears that the glyceride vehicles may not be optimal 
vehicles for dermatological formulations. However, it should 
be said with caution because, as mentioned earlier, vehicle 
effects can be and of ten are compound dependent and only two 
drugs have been evaluated in this study. 
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Four mixed commercial vehicles tested included two miglyols 
and two imwitors. MiglyolsR contain propylene glycol 
caprylate/dicaprylate. ImwitorsR contain propylene glycol 
dilaurates. The overall ranges of epidermal and dermal 
retention values for HC and TAC are about 2 to 2.6, indicating 
comparable effects of these vehicles on the local drug 
delivery. However, data show mixed results in terms of vehicle 
effects on HC versus TAC. For example, epidermal and dermal 
retentions of HC and TAC from Miglyol 840R were comparable. 
But, Miglyol 812R provided over 3 fold higher epidermal and 
about 1. 3 fold higher dermal retention of HC. Imwitor 412R 
showed a flip-flop behavior. It provided 1. 5 fold higher 
epidermal but, 1.6 fold lower dermal retention of HC than TAC. 
Imwitor 408R, on the other hand, showed almost twice epidermal 
retention but, comparable dermal retention. These vehicles 
appear to be efficient in providing local drug delivery. The 
magnitudes of retentions obtained are on the higher side when 
considering all 26 vehicles evaluated. There is an interesting 
feature which these mixed commercial vehicles offer. They seem 
to provide high epidermal as well as high dermal retention 
along with less than 5 fold difference between the retention 
in the two layers for both drugs studied. While it may be a 
desirable feature, note that it does not happen with all 
drugs. For example, the ratios of epidermal to dermal 
retentions of Ro 24-5413 and Ro 24-0238 were reported to be 
far in excess of five 22 • 23 
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Five commonly known enhancers were also evaluated as vehicles 
in the present study. The ranges of epidermal and dermal 
retentions from these vehicles were found to be 6.3 fold and 
2.8 fold for HC, respectively and 3.2 fold and 3.4 fold for 
TAC, respectively. Apparently, these enhancers do not seem to 
affect the local drug delivery of HC and TAC similarly. DMSO 
showed a rather large difference with regard to the epidermal 
versus dermal retention values, about 4.2 fold higher 
retention in the epidermis than dermis for both drugs tested. 
This ratio is in the range of 0.39 fold to 1.7 fold for the 
other four enhancers, oleic acid, AzoneR, linoleic acid and 
TranscutolR. The results obtained with DMSO are rather 
disappointing with regard to the dermal retention observed. It 
is probably the most widely studied and "admired" enhancer as 
reported in the literature. But, a careful analysis indicates 
that such "sentiments" about DMSO were primarily derived from 
permeation/flux data as opposed to retention data. Actually, 
there are virtually no reports on the utility of DMSO in 
enhancing local drug delivery. 
Oleic acid has been fairly well studied enhancer. However, 
almost all of the literature reports are about the enhancing 
effects on drug permeation/flux as opposed to drug retention. 
It provided an equal retention of HC in the epidermal and 
dermal layers. But, for TAC, it showed 2. 5 fold higher 
retention in the dermal layer. 
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AzoneR is an another extensively studied compound for its 
effects on drug permeation. It has been found to enhance the 
permeation of a vast number of compounds31 • 195 • Its effects on 
the epidermal and dermal retention of HC and TAC, however, 
were found to be only modest. The effects of TranscutolR on 
the epidermal and dermal retentions of HC and TAC were 
observed to be somewhat lower than AzoneR. The effects of 
linoleic acid on the local delivery of HC and TAC were also 
found to be modest. The dermal delivery was noted to be about 
twice as high as the epidermal delivery. 
Retention data for HC and TAC from all vehicles are ranked in 
Tables 9 and 10, respectively. The vehicles were ranked in a 
descending order of the epidermal retention. The corresponding 
dermal rank orders are also provided in the same tables. The 
epidermal retention values vary over ranges of 110 fold and 
463 fold for HC and TAC, respectively. The corresponding 
dermal retention ranges are 67 fold and 84 fold for HC and 
TAC, respectively. These are extremely large ranges observed 
and point to the strength of vehicle effects on local drug 
delivery. For both drugs, propylene glycol provided maximal 
and PEG 400 provided minimal epidermal retention. This 
observation is of special importance because both of these 
vehicles are quite commonly used in dermatological 
formulations. 
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The top five vehicles for HC retention on the basis of the 
mean retention values in the epidermis are propylene glycol, 
DMSO, ethylene glycol, Imwitor 408 and Miglyol 812R, and for 
the dermal retention, isostearyl alcohol, Miglyol 840R, 
Imwitor 408 R, isopropyl palmitate and Miglyol 812R (Tables 9 
and 10 ) . The top five vehicles for retention of TAC on the 
basis of the mean retention values in the epidermis are 
propylene glycol, ethylene glycol, DMSO, triolein and Miglyol 
840, and for the dermal retention, they are isopropyl 
palmitate, Miglyol 840R, Imwitor 408 R, isopropyl myristate and 
Imwi tor 412R. 
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Table 9. Ranking of All Vehicle s Tested According to the 
Percentage of Dose of Hydrocorti s one Retained in the Hairless 
Ra t Epide rma l Skin Layer . 
# VEHICLES PERCENT RETAINED ± S . D. 
EPIDERMIS DERMIS 
1. Propylene 4.75 ± 0.856 1.15 ± 
Glycol 
2. Dimethyl 3.60 ± 1. 03 0.838 
Sulfoxide 
3. Ethylene Glycol 3.60 ± 1. 97 1.09 ± 
4. Imwitor 408R 3.56 ± 1. 67 2.53 ± 
5. Miglyol 812R 3.52 ± 1. 02 1.99 ± 
6. Diethylene 2.80 ± 0.508 1.32 ± 
Glycol 
7. Isostearyl 2.78 ± 0.320 3.82 ± 
Alcohol 
8 . Miglyol 840R 2.41 ± 0.226 3.06 ± 
9. Isopropyl 1. 73 ± 0.534 2.24 ± 
Palmitate 
10. Isopropyl 1. 71 ± 0.847 1 . 58 ± 
Myr istate 
11. Tributyrin 1. 63 ± 0.391 0 . 779 
12. Oleic Acid 1. 55 ± 0 . 249 1. 84 ± 
13. Imwitor 412R 1. 52 ± 0. 511 1.17 ± 
14. Ethanol 1. 36 ± 0.395 0.230 
15. Isopropanol 1. 27 ± 0.302 0.142 
16. Tricaprylin 1. 03 ± 0.124 1.13 ± 
17. AzoneR 0.970 ± 0.260 1. 40 ± 
18. Linoleic Acid 0 . 815 ± 0.617 1. 60 ± 
19. Triolein 0.646 ± 0.179 0.258 
20. Monoacetin 0.621 ± 0 . 116 0.319 
21. Tr anscutolR 0.567 ± 0.141 0.640 
22. Diacetin 0.145 ± 0. 00165 0 . 198 
23. PEG 300 0.145 ± 0 . 119 0.0843 
24. Triacetin 0.129 ± 0.0323 0 .137 
25 . PEG 200 0.106 ± 0.02 0.0613 
26. PEG 400 0.043 ± 0.0295 0.0570 
Rank A: Ranking of Vehicles by \ of Dose Retained in Epidermis 
Rank B: Ranking by Vehicles by \ of Dose Retained in Dermis 
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0.533 
± 0.483 
0.425 
0.459 
0.652 
0.317 
1. 90 
0.398 
0.320 
0.225 
± 0.220 
0.150 
0.136 
± 0.0857 
± 0.0305 
0.154 
0.0709 
0 . 542 
± 0.0311 
± 0.1 5 9 
± 0.100 
± 0.0991 
± 0.0186 
± 0.0578 
± 0 . 00808 
± 0.00346 
RANK 
A B 
1 12 
2 15 
3 14 
4 3 
5 5 
6 10 
7 1 
8 2 
9 4 
10 8 
11 16 
12 6 
13 11 
14 20 
15 22 
16 13 
17 9 
18 7 
19 19 
20 18 
21 17 
22 21 
23 24 
24 23 
25 25 
26 26 
Table 10 . Ranking of All Vehicles Tested According to the 
Percentage of Dose of Triamcinolone Acetonide Retained in the 
Hairless Rat Epiderma l Skin Layer . 
#'s VEHICLES PERCENTAGE OF DOSE RETAINED ± S . D . 
EPIDERMI S DERMI S 
1. Propylene 5.09 ± 1. 47 0.769 ± 0.422 
Glycol 
2. Ethylene Glycol 4.41 ± 1. 37 1. 61 ± 1. 09 
3. Dimethyl 2.21 ± 0 . 622 0.525 ± 0.103 
Sulfoxide 
5 . Miglyol 840R 2.44 ± 0 . 373 2.98 ± 0.255 
4. Triolein 2.18 ± 1. 32 0.809 ± 0.268 
6. Isopropyl 1. 92 ± 0 . 249 3. 71 ± 2.80 
Palmitate 
7 . Imwitor 408R 1. 85 ± 0.762 2.50 ± 0.709 
8. Isopropyl 1. 84 ± 0.526 1. 89 ± 0 .131 
Myristate 
9. Tributyrin 1.64 ± 0 . 442 1 . 09 ± 0.107 
10. Tricaprylin 1. 62 ± 0.0961 0.699 ± 0.0862 
11. Miglyol 812R 1. 07 ± 0 . 302 1.56 ± 0.589 
12. TranscutolR 1 . 06 ± 0 . 267 0 . 614 ± 0.190 
13. Imwitor 412R 0.975 ± 0.370 1.84 ± 0.272 
14. AzoneR 0.967 ± 0.216 1.12 ± 0.144 
15. Linoleic Acid 0.898 ± 0.0835 1. 66 ± 0.441 
16. Isopropanol 0.885 ± 0.417 0.172 ± 0.0359 
17. Di ethylene 0 . 857 ± 0.246 0.182 ± 0 . 0767 
Glycol 
18. Ethanol 0.755 ± 0.273 0 . 311 ± 0.0945 
19. Oleic Acid 0.682 ± 0.214 1.77 ± 0.514 
20 . Monoacetin 0.640 ± 0.532 0.203 ± 0.0777 
21. Isostearyl 0.452 ± 0.156 0. 721 ± 0.206 
Alcohol 
22. Triacetin 0 . 157 ± 0 . 0661 0 . 196 ± 0 . 0480 
23. PEG 200 0 . 110 ± 0.0437 0.0707 ± 0.0422 
24 . Diacetin 0.0643 ± 0.0240 0.0440 ± 0.0137 
25 . PEG 300 0.0423 ± 0.0150 0.0463 ± 0.00850 
26. PEG 400 0. 011 ± 0.000954 0.0473 ± 0.00451 
Rank A: Ranking of Vehicles by % of Dose Retained in Epidermis 
Rank B: Ranking by Vehicles by % of Dose Retained in Dermis 
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RANK 
A B 
1 13 
2 8 
3 17 
5 2 
4 12 
6 1 
7 3 
8 4 
9 11 
10 15 
11 9 
12 16 
13 5 
14 10 
15 7 
16 22 
17 21 
18 18 
19 6 
20 19 
21 14 
22 20 
23 23 
24 26 
25 25 
26 24 
( 
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These observations indicate the following: 
a. Within a given skin layer, epidermis or dermis, drug 
retention was dependent on the drug used. 
b. For a given drug, the ranking of vehicles was not same 
for epidermis and dermis. 
c. The ranges of the epidermal and dermal retention for 
either drug are substantially large and underscore the 
critical importance of proper vehicle selection. 
d. Reasons for such diverse effects are not clear at this 
time. However, the clue may lie in the fact that the 
vehicles themselves are absorbed in the skin layers. This 
would change the "microenvironment 11 in the tissue and the 
thermodynamic rules of transport processes will not be 
followed. How changes in the microenvironment affect drug 
delivery is a complex issue and elucidation of possible 
mechanisms is out of the scope of this thesis. 
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4.3.2. Drug Retention and Lipophilicity: 
TAC, belong to the same therapeutic 
The two drugs HC and 
class and both are 
glucocorticoids used as anti-inflammatory agents having 
comparable molecular weights. These compounds, however, differ 
with respect to solubility in water and partition 
coefficients. HC is more water soluble than TAC and has a 
lower ether/water partition coefficient, e.g . 1.3 vs 13.1. 
These properties may indicate that the skin uptake may be 
distinguishable. As it is apparent from the foregoing 
discussion, this is not the case. Also, the solubility of HC 
and TAC in the vehicles studied is not distinguishable. The 
reasons for the skin uptake data not to follow the drugs' 
partition coefficients, are not clear. 
4.3.3. Drug Retention and Solubility: The ranges of solubility 
values of HC and TAC was found to be, 1912 and 2297, 
respectively, in the 26 vehicles studied. The ranges observed 
in the epidermal and dermal retentions of HC are 110 and 67, 
respectively (Table 9) . For TAC, the ranges of epidermal and 
dermal retentions are 462 and 84, respectively (Table 10). To 
further examine the relationship between retention and 
solubility, the epidermal and dermal retention data were 
plotted as a function of solubility separately for each class 
of vehicles studied for both drugs (Figures 6-12). Each of 
these figures contains four plots, A-D, which include 
epidermal and dermal plots for both drugs studied. 
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Figure 6. Percent Retention vs Solubility Plot s of 
Hydrocortisone(HC) c:.nd Triamcin olone Acetonide(TAC) 
in the Epidermis and Dermis fo r the Three "Glycol" 
Vehicles Studied in the in Vivo Hairless Rat Model. 
A: HC in Epidermis 
C: TAC in Epidermis 
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Hydrocortisone(HC) and Triamcinolone Acetonide(TAC) 
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Vehicles Studied in the In Vivo Hairless Rat Model. 
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Figure 10 . Percent Retention vs Solubility Plots of 
Hydrocortisone(HC) and Triamcinolone Acetonide(TAC) 
in the Epidermis and Dermis for the Six "G;ycerides" 
Vehicles Studied in the In Vivo Hairless Rat Model. 
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Hydrocortisone(HC) and Triamcinolone Acetonide(TAC) 
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in the Epidermis and Dermis for the Four "Comme.rcial" 
Vehicles Studied in the In Vivo Hairless Rat Model. 
A: HC in Epidermis 8: HC in Dermis 
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Figure 12. Percent Retention vs Solubility Plots of 
Hydrocortisone(HC) and Triamcinolone Acetonide(TAC) 
in the Epidermis and Dermis for the Five "Enhancers" 
Vehicles Studied in the In Vivo Hairless Rat Model. 
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Figure 6 contains plots for the three glycol vehicles tested. 
The epidermal retention of HC showed a decline with solubility 
whereas the dermal retention showed an increase. The trend for 
the epidermal retention of TAC was an initial increase in 
retention followed by a decrease. This trend for the dermal 
retention was almost a linear decline with solubility. In 
addition to these differing trends, the rank order of the 
retention in epidermis vs dermis was also different for the 
two drugs. 
The retention values of three polyglycol vehicles were plotted 
against the solubilities in Figure 7. The trend in the 
epidermal retention of HC was similar to that in the dermis, 
both layers show an initial increase followed by a decrease in 
the drug uptake. The rank order for the three vehicles was 
also same. The situation is different for TAC where the 
epidermal retention showed a consistent increase in going from 
PEG 400 through PEG 300 to PEG 200. The dermal retention for 
PEG 400 was comparable to that from PEG 300. Retention from 
PEG 200 was about 50 % higher than the other PEGs. 
Similarly, the retention versus solubility data for the three 
alcohols was plotted in Figure 8. The epidermal retention of 
HC declined sharply in going from isostearyl alcohol to 
isopropanol and remained invariant from ethanol. A similar 
trend was observed for the dermal retention except that the 
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decline from isostearyl alcohol to isopropanol was much 
sharper. The trend observed for the epidermal retention of TAC 
was different. The retention first increased in going from 
isostearyl alcohol to isopropanol followed by a decrease from 
ethanol. The dermal trend for TAC was opposite to the 
epidermal trend. 
Figure 9 contains plots for the two esters studied. The 
epidermal retention of HC remained invariant in going from 
isopropyl palmitate to isopropyl myristate but, a decrease in 
the dermal retention was noted. For TAC, the epidermal 
retention was comparable for the two vehicles but, the dermal 
retention showed almost a doubling of the dermal retention in 
going from isopropyl myristate to isopropyl palmitate. 
Plots of skin layer retention versus solubility were made for 
the six glyceride vehicles studied (Figure 10). The epidermal 
and dermal retention showed a general decrease with solubility 
for both drugs studied. However, the rank orders of the 
vehicles was different between the epidermal and dermal 
retention for both drugs. 
Figure 11 contains plots for the four mixed commercial 
vehicles studied. At first glance, the epidermal and dermal 
retention of HC seem to show a decrease with solubility. Upon 
further examination, it became clear that the epidermal 
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retention first decreased in going from Miglyol 812R to 
Miglyol 840R followed by an increase from Imwitor 408R and a 
decrease from Imwitor 412R. The dermal retention behaved 
differently in that initially there was an increase in going 
from Miglyol 812R to Miglyol 840R followed by an almost linear 
decrease in going from Miglyol 840R through Imwitor 408R to 
Imwi tor 412R. For TAC, the epidermal and dermal retention 
showed an initial decrease in going from Miglyol 840R to 
Miglyol 812R followed by an increase, however, the rank orders 
of the vehicles were not same. 
Finally the plot of retention versus solubility were made for 
the five enhancer vehicles studied (Figure 12). For both, HC 
and TAC, general increase in the epidermal retention was 
observed with solubility, DMSO showing the maximal retention. 
The rank orders of the vehicles were not same. The dermal 
retention showed a decrease with solubility, transcutolR and 
DMSO showing lowest values. 
The trends discussed above between drug retention in epidermis 
and dermis, and drug solubility are quite interesting and 
revealing. As can be seen, no definite trends were observed. 
For most part, epidermis behaved differently from the dermis 
and HC behaved differently from TAC with regard to epidermis 
and/or dermis. Therefore, it would appear that drug solubility 
alone can not aid in predicting drug uptake in the skin 
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layers. This emphasizes the point raised earlier22 • 23 as to the 
( importance of the uptake of vehicles in the epidermis and 
dermis. Vehicles certainly permeate into the skin and are 
retained there. This changes the "microenvironment" in the 
skin which is certain to alter drug retention. Until more 
thorough studies are carried out to better understand the 
complex drug/vehicle / skin interactions, it probably would not 
be feasible to make predictions on what vehicles would provide 
optimal drug delivery. 
4.3.4. Criteria for Formulation Selection- Retention vs Flux: 
Some information was presented in the Introduction Section of 
this thesis on the relevance of drug uptake in the skin layers 
as a criterion of choice over flux. Data gathered in this 
study indirectly support the contention that flux data do not 
necessarily provide correct information for selecting vehicles 
for dermatological formulations. To emphasize this point, 
ratios of epidermal to dermal retention were computed and 
ranked in a descending order. These results are presented in 
Tables 11 and 12 for HC and TAC, respectively. 
The ratios range from 8. 94 to 0. 510 a range of about 18 
fold, for HC and 6.62 to 0.223, a range of about 30 fold, for 
TAC. Vehicles showing ratios of 1 or less provide better 
dermal deli very of drugs. It is an important observation 
because for certain diseases, a better dermal delivery may be 
needed. The rank orders of the ratios for the two drugs are 
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not same. This strongly indicates that different vehicles 
affect the skin layers differently and provide varying tissue 
drug concentrations. To use flux values for screening 
formulations, the ratios obtained should have been constant. 
Results obtained in this study show that there is need to 
experimentally determine drug retention in the skin layers to 
screen dermatological formulations for topical drug delivery. 
85 
I 
4.3.5 Utility of the In Vivo Model for Screening Vehicles-
Significance of the Present Study: Dermatological formulations 
of ten contain several excipients. As seen in Table 3, a 
formulator needs to select his excipients from a rather large 
list. Until recently, when local drug delivery was recognized 
as a criterion for formulation selection, the only available 
criteria included cosmetic acceptability, lack of irritation 
of the product and stability of the drug. Given the current 
state of knowledge and awareness, one can make more judicious 
choices of vehicles/excipients based on data on drug delivery. 
The in vivo hairless rat model used in this study can be 
useful in this regard. Many pertinent vehicles can be screened 
readily for their effects on drug retention in the desired 
skin layer and vehicles which provide maximal delivery can be 
selected for formulation development. Unfortunately, no 
predictive 11 tools" are yet available to predict optimal 
vehicles. One has to experimentally screen all potential 
vehicles. This becomes quite clear from data presented in this 
thesis. A given vehicle may be effective for a certain drug 
and not for another. It may be a good vehicle for providing 
optimal epidermal retention and not dermal retention. Until 
the state of the art advances in this area, a reliance on the 
experimental observations will have to continue. 
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5.0 SUMMARY AND CONCLUSIONS 
An in vivo hairless rat model was used in this study to 
evaluate the effects of vehicles on the local drug delivery to 
the skin layers. For this purpose, two model drugs, 3H-
hydrocortisone (HC) and 3H-triamcinolone acetonide (TAC) , and 
26 vehicles were investigated. These drugs were chosen due to 
their differing lipophilicities. The vehicles selected 
belonged to seven different classes, e.g. glycols, 
polyglycols, alcohols, esters, glycerides, mixed commercial 
vehicles and enhancer vehicles. 
The solubility of HC and TAC was determined in all 26 vehicles 
chosen. A high performance liquid chromatography (HPLC) method 
was established for analyzing drug concentrations in the 
solubility samples. The method adopted has the advantage that 
it provided interference free results for 26 different 
vehicles, for two different drugs. The solubility data showed 
rather large ranges, 1912 fold for HC and 2297 fold for TAC 
indicating the value of selecting these vehicles. Such large 
solubility differences, when compared with the observed 
respective drug uptake data, was expected to reveal a lot of 
useful information. 
Formulations of HC and TAC were prepared in vehicles at half 
of the respective solubilities. The formulations contained 
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both radiolabelled {3H-labelled) and regular forms of the 
drugs. The formulations were applied on the animal's skin in 
a "finite dose" manner which amounted to 2 µL of the drug 
solution applied per cm2 of the skin. 
The animal model used was an in vivo hairless rat model 
similar to what has been used at Hoffmann-La Roche, Inc. for 
screening dermatological formulations for drug delivery. The 
formulation was applied on the abdominal skin of anesthetized 
rats for a three hour period. At that time, the excess 
formulation was wiped off the skin by using a "top wash" 
procedure. The animal was sacrificed and the skin was excised 
and sectioned into the epidermis and dermis and weighed. The 
drug was extracted from the skin layers by using a tissue 
oxidizer and analyzed by using a liquid scintillation counter. 
The drug uptake in the tissue was expressed in terms of drug 
concentration per gram of the tissue and in terms of percent 
of the applied dose retained in the skin layers. 
The drug retention data were ranked in a descending order of 
percent epidermal and dermal retention values. The percent 
epidermal to dermal retention ratios were computed. Also, the 
percent retention data were plotted as a function of drug 
solubility separately for the seven classes of vehicles used. 
Interpretations of these results indicate the following 
findings: 
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Table 11. Ratios of Epidermal to Dermal Retention of 
Hydrocortisone From Different Vehicles in Hairless Rat Skin. 
# Vehicles Ratios of Epidermal to Dermal Ranking 
Retention 
1 . Isopropanol 9 . 04 ± 1.36 1 
2 . Ethanol 6 . 59 ± 3.14 2 
3. Dimethyl 6 . 12 ± 4.78 3 
Sulfoxide 
4. Propylene Glycol 5.27 + 3 . 69 4 
5. Ethylene Glycol 3.30 ± 1. 08 5 
6 . Triolein 2.55 ± 0.835 6 
7 . Diethylene Glycol 2 . 24 ± 0.846 7 
8. Monoacetin 2.23 ± 0.897 8 
9. Tributyrin 2.13 ± 0 . 383 9 
10. Miglyol 812R 1. 89 ± 0.860 10 
11. PEG 300 1. 75 ± 1. 61 11 
12. PEG 200 1.73 ± 0 . 310 12 
13 . Imwitor 408R 1. 50 + 0 . 847 13 
14. Imwitor 412R 1. 32 ± 0.542 14 
15. Isopropyl 1.12 ± 0.626 1 5 
Myristate 
16. Triacetin 1. 01 ± 0.292 16 
17. Tricaprylin 0.937 ± 0.247 17 
18. TranscutolR 0.880 ± 0.150 18 
19. Diacetin 0 . 868 ± 0.421 19 
20 . Isostearyl 0.866 ± 0.422 20 
Alcohol 
21. Oleic Acid 0.848 ± 0.186 21 
22. Miglyol 840R 0 . 803 ± 0 .171 22 
23 . Isopropyl 0.760 ± 0.166 23 
Palmitate 
24. PEG 400 0.754 ± 0.488 24 
25 . AzoneR 0.700 ± 0 . 209 25 
26. Linoleic Acid 0 . 468 ± 0.261 26 
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Table 12. Ratios of 
Triamcinolone Acetonide 
Rat Skin. 
Epidermal to Dermal Retention of 
From Different Vehicles in Hairless 
# VEHICLES Ratios of Epidermal to Dermal Ranking 
Retention 
1. Propylene 9.35 ± 7 . 52 1 
Glycol 
2. Isopropanol 5.37 ± 3.19 2 
3. Diethylene 5 . 01 ± 1. 37 3 
Glycol 
4. Dimethyl 4.25 ± 1. 07 4 
Sulfoxide 
5. Ethylene Glycol 4.16 ± 3 . 19 5 
6 . Monoacetin 3.70 ± 3.95 6 
7 . Trio le in 2 . 56 ± 0.840 7 
8 . Ethanol 2 . 41 ± 0 . 243 8 
9 . Tricaprylin 2.34 ± 0 . 387 9 
10. PEG 200 2 . 00 ± 1.57 10 
11 . Transcutol R 1.98 ± 1. 23 11 
12 . Tributyrin 1. 51 ± 0 . 405 12 
13. PEG 300 1.48 ± 1.17 13 
14 . Diacetin 1.44 ± 0.151 14 
15 . Isopropyl 0.968 ± 0.240 15 
Myristate 
16 . AzoneR 0.876 ± 0.251 16 
17. Miglyol 840R 0.821 ± 0 .113 17 
18. Imwitor 408R 0.805 ± 0.490 18 
19. Triacetin 0.787 ± 0 . 163 19 
20. Miglyol 812R 0.783 ± 0.405 20 
21 . Isopropyl 0.732 ± 0.431 21 
Palmitate 
22 . Isostearyl 0.696 ± 0.430 22 
Alcohol 
23 . Linoleic Acid 0 . 576 ± 0 . 196 23 
24. Imwitor 412R 0.542 ± 0 . 230 24 
25 . Oleic Acid 0 . 419 ± 0 . 208 25 
26 . PEG 400 0.234 ± 0 . 204 26 
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• The epidermal and dermal retention of HC and TAC can be 
affected rather dramatically by the choice of vehicles. 
For example, the epidermal and dermal retention ranged 
110 and 67 fold, respectively for HC, and 462 and 84 
fold, respectively for TAC. 
• The overall rank order of vehicles for epidermal 
retention was different than the dermal retention for 
both HC and TAC. This indicated that the epidermal and 
dermal retentions were affected differently for the same 
drug. Also, the magnitudes of the effects noted for HC 
are quite different than those for TAC. 
• The rank order comparisons for epidermal and dermal 
retentions within different classes of the vehicles 
studied indicated that four out of seven classes provided 
different rank orders for HC and six out of seven classes 
provided different rank orders for TAC. 
• The rank order of epidermal to dermal retention ratios 
for HC was different than for TAC, again emphasizing that 
vehicles effects vary substantially from drug to drug. 
The present studies are important in many respects. The type 
of in vivo studies done here are useful in selecting 
vehicle (s) for dermatological formulations. Unfortunately, 
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these studies also indicate that the state of the art known in 
this area is insufficient to make prediction on the choice of 
vehicles. Solubility of drugs in vehicles is not necessarily 
related to the local drug delivery. Drug delivery scientists 
have to resort to the experimental approach to select 
vehicle(s). The observations made in this study, e.g. varying 
rank orders and ranges, support the contention that selection 
of vehicles for these two drugs should be based on the 
experimental determination of retention data instead of flux 
data. 
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Table A.1. In Vivo Retention of Hydrocortisone From Azone 
in the Epidermis and Dermis of Hairless Rat Skin. Dose Applied 
= 20 µL of 23.2 mg/mL Solution Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 120.4 125.3 142.3 129.3 ± 11.5 
Retained 
(µ.g/G) 
Epidermal 24.6 39.1 35.1 32.9 ± 7.48 
Wt. (mg) 
% of Dose 0.671 1.11 1.13 0.970 ± 0.260 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 11.5 10.9 12.2 11.5 ± 0.651 
Retained 
(µg/G) 
Dermal Wt. 561.8 533.2 511.8 535.6 ± 25.1 
(mg) 
% of Dose 1.46 1. 32 1. 41 1.40 ± 0.0709 
Retained 
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Table A. 2. In Vivo Retention of Hydrocortisone From 
Diacetin in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 8.65 mg Solution Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 5.87 8.11 7.54 7.17 ± 1.16 
Retained 
(µg/G) 
Epidermal 55.2 31.7 38.9 41.9 ± 12.0 
Wt. (mg) 
% of Dose 0.161 0.128 0.146 0.145 ± 
Retained 0.0165 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.410 1. 84 0.700 0.983 ± 0.756 
Retained 
(µg/G) 
Dermal Wt. 641.6 341.8 439.7 474.4 ± 152.9 
(mg) 
% of Dose 0.130 0.312 0.153 0.198 ± 0.0991 
Retained 
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Table A. 3. In Vivo Retention of Hydrocortisone From 
Diethylene Glycol in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 12.6 mg/mL Solution Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 151.8 236.1 171.2 186.4 ± 44.1 
Retained 
(µg/G) 
Epidermal 41.4 37.5 51.0 43.3 ± 6.95 
Wt. (mg) 
% of Dose 2.21 3.11 3.07 2.80 ± 0.508 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 11. 0 13.6 5.53 10.0 ± 4.12 
Retained 
(µg/G) 
Dermal Wt. 370.0 327.3 494.7 397.3 ± 87.0 
(mg) 
% of Dose 1.42 1.57 0.962 1. 32 ± 0.317 
Retained 
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Table A.4. In Vivo Retention of Hydrocortisone From 
Dimethyl Sulfoxide in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 143.42 mg/mL of Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 3782 2878 1867 2843 ± 958.3 
Retained 
(µg/G) 
Epidermal 18.2 43.5 55.0 38.9 ± 18.8 
Wt. (mg) 
% of Dose 2.50 4.56 3.74 3.60 ± 1.03 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 86.7 37.8 25.9 50.l ± 32.2 
Retained 
(µg/G) 
Dermal Wt. 409.0 650.0 350.0 469.6 ± 158.9 (mg) 
% of Dose 1.29 0.895 0.330 0.838 ± 0.483 
Retained 
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Table A. 5. In Vivo Retention of Hydrocortisone From 
Ethylene Glycol in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 6.20 mg/mL of Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 117.0 138.0 184.9 146.6 ± 34.8 
Retained 
(µg/G) 
Epidermal 31.8 22.4 43.8 32.6 ± 10.7 
Wt. (mg) 
% of Dose 2.69 2.24 5.86 3.60 ± 1.97 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 5.12 4.09 5.79 5.00 ± 0.85 
Retained 
(µg/G) 
Dermal Wt. 180.1 367.8 362.1 303.3 ± 106.8 
(mg) 
% of Dose 0.67 1.09 1.52 1.09 ± 0.425 
Retained 
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Table A.6. In Vivo Retention of Hydrocortisone From Ethanol 
in the Epidermis and Dermis of Hairless Rat Skin. Dose Applied 
= 20 µL of 5.05 mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 18.7 26.1 31.4 25.4 ± 6.38 
Retained 
(µg/G) 
Epidermal 47.3 54.6 51. 5 51.l ± 3.66 
Wt. (mg) 
~ 0 of Dose 0.919 1.48 1. 68 1. 36 ± 0.395 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.306 0.399 0.207 0.304 ± 0.0960 
Retained 
(µg/G) 
Dermal Wt. 672.1 779.5 714.0 721.9 ± 54.1 
(mg) 
% of Dose 0.214 0.323 0.154 0.230 ± 0.0857 
Retained 
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Table A.7. In Vivo Retention of Hydrocortisone From Imwitor 
408R in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied= 20 µL of 4.16 mg/mL Solution Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 65.1 41.9 50.6 52.5 ± 11. 7 
Retained 
(µg/G) 
Epidermal 59.8 32.1 63.2 51. 7 ± 17.1 
Wt. (mg) 
% of Dose 4.93 1. 70 4.05 3.56 ± 1. 67 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 2.62 3.96 3.02 3.20 ± 0.688 
Retained 
(µg/G) 
Dermal Wt. 683.8 610.6 591.4 628.6 ± 48.8 
(mg) 
% of Dose 2.27 3.06 2.26 2.53 ± 0.459 
Retained 
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Table A.8. In Vivo Retention of Hydrocortisone From Imwitor 
412R in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied = 20 µL of 11.2 mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 56.6 51.9 60.3 56.3 ± 4.21 
Retained 
(µg/G) 
Epidermal 76.1 50.5 39.9 55.5 ± 18.6 
Wt. (mg) 
% of Dose 2.11 1. 28 1.18 1.52 ± 0.511 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 4.12 3.89 5.26 4.42 ± 0.734 
Retained 
(µg/G) 
Dermal Wt. 538.7 575.5 516.7 543.6 ± 29.7 (mg) 
% of Dose 1.09 1.10 1.33 1.17 ± 0.136 
Retained 
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Table A. 9. In Vivo Retention of Hydrocortisone from 
Isopropanol in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20µL of 2.23 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 10.1 8.62 8.33 9.02 ± 0.949 
Retained 
(µg/G) 
Epidermal 73.6 60.0 58.9 64.2 ± 8.19 
Wt. (mg) 
% of Dose 1. 62 1.13 1.07 1.27 ± 0.302 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.136 0.0950 0.130 0.120 ± 0.0221 
Retained 
(µg/G) 
Dermal Wt. 575.6 531.5 586.4 564.5 ± 29.1 (mg) 
% of Dose 0.172 0.111 0.142 0.142 ± 0.0305 
Retained 
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Table A.10. In Vivo Retention of Hydrocortisone from 
Isopropyl Myristate in the Epidermis and Dermis of Hairless 
Rat Skin. Dose Applied = 20 µL of 0 .16 mg/mL of Solution 
Appplied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 1.55 1.29 1.72 1.52 ± 0.217 
Retained 
(µg/G) 
Epidermal 41.8 16.5 36.4 31.6 ± 13.3 
Wt. (mg) 
% of Dose 2.23 0.73 2.16 1.71 ± 0.847 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.0590 0.113 0.0657 0.0792 ± 0.0294 
Retained 
(µg/G) 
Dermal Wt. 839.4 438.5 582.1 620.0 ± 203.1 (mg) 
% of Dose 1. 71 1.71 1.32 1. 58 ± 0.225 
Retained 
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Table A.11. In Vivo Retention of Hydrocortisone from 
Isopropyl Palmitate in the Epidermis and Dermis of Hairless 
Rat Skin. Dose Applied = 20 µL of 0. 09 mg/mL of Solution 
Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 1.13 0.822 1.14 1. 03 ± 0.181 
Retained 
(µg/G) 
Epidermal 29.4 22.1 28.9 26.8 ± 4.08 
Wt. (mg) 
% of Dose 2.05 1.11 2.02 1.73 ± 0.534 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.0887 0.0699 0.0694 0.0760 ± 0.0110 
Retained 
(µg/G) 
Dermal Wt. 468.6 446.4 524.1 479.7 ± 40.0 
(mg) 
% of Dose 2.56 1.92 2.24 2.24 ± 0.320 
Retained 
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Table A.12. In Vivo Retention of Hydrocortisone from 
Isostearyl Alcohol in Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied = 20 µL of 0.57 mg/mL of Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 5.87 8.11 7.54 7.17 ± 1.16 
Retained 
(µ.g/G) 
Epidermal 55.2 31.7 39.0 42.0 ± 12.0 
Wt. (mg) 
% of Dose 3.09 2.45 2.80 2.78 ± 0.320 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.410 1.84 0.700 0.983 ± 0.756 
Retained 
(µ.g/G) 
Dermal Wt. 641.6 341.8 439.7 474.4 ± 152.9 
(mg) 
% of Dose 2.5 6.00 2.94 3.82 ± 1. 90 
Retained 
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Table A.13. In Vivo Retention of Hydrocortisone from 
Linoleic Acid in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 6.11 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 32.6 22.9 17.5 24.3 ± 7.65 
Retained 
(µg/G) 
Epidermal 52.4 35.5 16.9 34.9 ± 17.8 
Wt. (mg) 
% of Dose 1.48 0.704 0.260 0.815 ± 0.617 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 3.40 3.61 2.02 3.01 ± 0.864 
Retained 
(µg/G) 
Dermal Wt. 660.0 603.0 556.0 606.3 ± 52.1 
(mg) 
% of Dose 1.94 1. 88 0.973 1.60 ± 0.542 
Retained 
125 
Table A.14. In Vivo Retention of Hydrocortisone from 
Monoacetin in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 6.11 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 18.2 10.1 11.1 13.1 ± 4.42 
Retained 
(µg/G) 
Epidermal 57.9 71. 5 83.0 70.8 ± 12.6 
Wt. in mg 
~ 0 of Dose 0.728 0.497 0.637 0.621 ± 0.116 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 1.35 0.460 0.841 0.884 ± 0.447 
Retained 
(µg/G) 
Dermal Wt. 502.4 480.8 575.6 519.6 ± 49.7 
(mg) 
% of Dose 0.469 0.153 0.334 0.319 ± 0.159 
Retained 
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Table A.15. 
Miglyol 812R in 
Dose Applied = 
cm2 • 
Epidermis 
Parameters 
Drug 
Retained 
(µg/G) 
Epidermal 
Wt. (mg) 
% of Dose 
Retained 
Dermis 
Parameters 
Drug 
Retained 
(µg/G) 
Dermal Wt. 
(mg) 
% of Dose 
Retained 
In Vivo Retention of Hydrocortisone from 
the Epidermis and Dermis of Hairless Rat Skin. 
20 µL of 0.21 mg/mL Solution Applied Over 10 
Animal Animal Animal Average ± 
1 2 3 S.D. 
5.09 4.45 3.58 4.38 ± 0.760 
53.5 69.5 47.3 56.8 ± 11. 5 
3.83 4.35 2.38 3.52 ± 1.02 
Animal Animal Animal Average ± 
1 2 3 S.D. 
0.399 0.184 0.222 0.268 ± 0.115 
485.2 583.6 548.3 539.0 ± 49.9 
2.73 1.51 1. 72 1.99 ± 0.652 
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Table A.16. 
Miglyol 840R in 
Dose Applied = 
cm2 • 
Epidermis 
Parameters 
Drug 
Retained 
(µg/G) 
Epidermal 
Wt. (mg) 
% of Dose 
Retained 
Dermis 
Parameters 
Drug 
Retained 
(µg/G) 
Dermal Wt. 
(mg) 
% of Dose 
Retained 
In Vivo Retention of Hydrocortisone From 
the Epidermis and Dermis of Hairless Rat Skin. 
20 µL of 0.45 mg/mL Solution Applied Over 10 
Animal Animal Animal Average ± 
1 2 3 S.D. 
8.08 11.0 11. 0 10.0 ± 1.69 
48.8 30.l 35.2 38.0 ± 9.67 
2.56 2.15 2.52 2.41 ± 0.226 
Animal Animal Animal Average ± 
1 2 3 S.D. 
0.849 1. 05 0.903 0.934 ± 0.104 
469.8 488.9 552.2 503.6 ± 43.1 
2.60 3.33 3.24 3.06 ± 0.398 
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Table A.17. In Vivo Retention of Hydrocortisone From Oleic 
Acid in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied= 20 µL of 0.07 mg/mL Solution Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.456 0.446 0.530 0.477 ± 0.0459 
Retained 
(µg/G) 
Epidermal 50.0 51.9 32.2 44.7 ± 10.9 
Wt. (mg) 
% of Dose 1.68 1.70 1.26 1.55 ± 0.249 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.0439 0.0358 0.0439 0.0412 ± 0.00468 
Retained 
(µg/G) 
Dermal Wt. 593.9 633.4 601.7 609.7 ± 20.9 
(mg) 
% of Dose 1.92 1. 67 1.94 1. 84 ± 0.150 
Retained 
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Table A.18. In Vivo Retention of Hydrocortisone From PEG 
200 in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied = 20 µL of 11.9 mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 7.60 7.02 4.05 6.22 ± 1. 90 
Retained 
(µg/G) 
Epidermal 38.4 45.l 56.1 46.5 ± 8.93 
Wt. (mg) 
% of Dose 0.111 0.120 0.0860 0.106 ± 0.0176 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.225 0.299 0.279 0.268 ± 0.0383 
Retained 
(µg/G) 
Dermal Wt. 634.5 617.1 566.2 605.9 ± 35.5 
(mg) 
% of Dose 0.0540 0.0700 0.0600 0.0613 ± 0.00808 
Retained 
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Table A.19. In Vivo Retention of Hydrocortisone From PEG 
300 in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied= 20 µL of 8.66 mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 8.88 4.76 6.37 6.67 ± 2.08 
Retained 
(µg/G) 
Epidermal 60.7 15.6 38.2 38.2 ± 22.6 
Wt. (mg) 
% of Dose 0.273 0.0380 0.123 0.145 ± 0.119 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.266 0.271 0.213 0.250 ± 0.0321 
Retained 
(µg/G) 
Dermal Wt. 611.8 756.l 621.2 663.0 ± 80.7 (mg) 
% of Dose 0.0820 0.104 0.0670 0.0843 ± 0.0186 
Retained 
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Table A.20. In Vivo Retention of Hydrocortisone From PEG 
400 in the Epidermis and Dermis of Hairless Rat Skin. Dose 
Applied= 20 µL of 6.39 mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 1.27 1.41 3.46 2.05 ± 1. 23 
Retained 
(µg/G) 
Epidermal 47.8 31. 3 44.1 41.1 ± 8.66 
Wt. (mg) 
% of Dose 0.0310 0.0220 0.0770 0.043 ± 0.0295 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.217 0.185 0.183 0.195 ± 0.0191 
Retained 
(µg/G) 
Dermal Wt. 483.4 633.1 639.6 585.4 ± 88.4 (mg) 
% of Dose 0.0530 0.0590 0.0590 0.0570 ± 0.00346 
Retained 
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Table A.21. In Vivo Retention of Hydrocortisone From 
Propylene Glycol in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 6.00 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 187.5 166.1 206.9 186.8 ± 20.4 
Retained 
(µg/G) 
Epidermal 29.0 22.9 24.7 25.5 ± 3.13 
Wt. (mg) 
% of Dose 5.40 3.78 5.08 4.75 ± 0.856 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 5.13 4.55 2.59 4.09 ± 1. 33 
Retained 
(µg/G) 
Dermal Wt. 274.7 334.5 208.5 272.6 ± 63.0 
(mg) 
% of Dose 1. 40 1. 51 0.536 1.15 ± 0.533 
Retained 
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Table A.22. In Vivo Retention of Hydrocortisone From 
Triacetin in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 2.0 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 1.88 1.54 1. 88 1.77 ± 0.196 
Retained 
(µg/G) 
Epidermal 41. 0 31.1 29.2 33.8 ± 6.34 
Wt. (mg) 
% of Dose 0.165 0.103 0.118 0.129 ± 0.0323 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.177 0.0827 0.111 0.124 ± 0.0484 
Retained 
(µg/G) 
Dermal Wt. 502.0 427.8 597.6 509.1 ± 85.1 
(mg) 
% of Dose 0.191 0.0760 0.143 0.137 ± 0.0578 
Retained 
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Table A.23. 
Tributyrin in the 
Dose Applied = 20 
cm2 • 
In Vivo Retention of Hydrocortisone From 
Epidermis and Dermis of Hairless Rat Skin. 
µL of 0.12 mg/mL Solution Applied Over 10 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.862 1. 01 0.902 0.925 ± 0.0766 
Retained 
(µg/G) 
Epidermal 55.3 44.3 32.7 44.1 ± 11.3 
Wt. (mg) 
% of Dose 1. 92 1. 80 1.19 1.63 ± 0.391 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0352 0.0399 0.0338 0.0363 ± 0.00320 
Retained 
( µ.g I G) 
Dermal Wt. 534.5 631.8 420.2 528.8 ± 105.9 (mg) 
% of Dose 0.755 1. 01 0.572 0.779 ± 0.220 
Retained 
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Table A. 24. In Vivo Retention of Hydrocortisone From 
Tricaprylin in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 1.07 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug (µg/G) 8.50 14.3 11. 3 11.4 ± 2.90 
Epidermal 30.2 20.5 20.6 23.7 ± 5.51 
Wt. (mg) 
% of Dose 1. 01 1.16 0.915 1. 03 ± 0.124 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug (µg/G) 0.596 0.430 0.674 0.567 ± 0.125 
Dermal Wt. 496.4 566.6 473.7 512.2 ± 59.3 
(mg) 
~ 0 of Dose 1.16 0.958 1. 26 1.13 ± 0.154 
Retained 
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Table A. 2 5. In Vivo Retention of Hydrocortisone From 
Transcutol in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 11.9 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 37.9 54.5 48.4 46.9 ± 8.40 
Retained 
(µg/G) 
Epidermal 26.6 30.9 29.9 29.1 ± 2.25 
Wt. (mg) 
% of Dose 0.414 0.692 0.594 0.567 ± 0.141 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug (µg/G) 2.70 3.15 2.63 2.83 ± 0.282 
Dermal Wt. 522.1 585.2 545.3 550.9 ± 31. 9 (mg) 
~ 0 of Dose 0.578 0.756 0.588 0.640 ± 0.100 
Retained 
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Table A.26. In Vivo Retention of Hydrocortisone From 
Triolein in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 0.12 mg/mL Solution Applied over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.422 0.610 0.432 0.488 ± 0.106 
Retained 
(µg/G) 
Epidermal 28.3 24.2 19.3 23.9 ± 4.51 
Wt. (mg) 
g.. 
0 of Dose 0.661 0.818 0.460 0.646 ± 0.179 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.00925 0.0122 0.00994 0.0105 ± 0.00154 
Retained 
(µg/G) 
Dermal Wt. 442.1 385.8 523.9 450.6 ± 69.4 
(mg) 
% of Dose 0.226 0.261 0.288 0.258 ± 0.0311 
Retained 
138 
( 
APPENDIX B 
( 139 
( 
Table B.1. In Vivo Retention of Triamcinolone Acetonide 
From Azone in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of 23.3 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 115.0 138.2 118.4 123.9 ± 12.5 
Retained 
(µg/G) 
Epidermal 28.8 37.8 36.4 34.3 ± 4.84 
Wt. (mg) 
% of Dose 0.748 1.18 0.974 0.967 ± 0.216 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 10.2 9.02 8.61 9.28 ± 0.825 
Retained 
(µg/G) 
Dermal Wt. 547.6 549.3 504.9 533.9 ± 25.2 (mg) 
% of Dose 1. 27 1.12 0.983 1.12 ± 0.144 
Retained 
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Table B.2. In Vivo Retention of Triamcinolone Acetonide 
From Diacetin in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 7.53 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 2.86 3.35 1.81 2.67 ± 0.787 
Retained 
(µg / G) 
Epidermal 45 . 2 42.8 35.6 41.2 ± 5.00 
Wt. (mg) 
% of Dose 0.0740 0.0820 0.0370 0.0643 ± 0.0240 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.148 0.197 0.147 0.164 ± 0.0286 
Retained 
(µg/G) 
Dermal Wt. 560.2 495.0 348 . 3 467.8 ± 108.5 
(mg) 
% of Dose 0.0470 0.0560 0.0290 0.0440 ± 0.0137 
Retained 
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Table B.3. In Vivo Retention of Triamcinolone Acetonide 
From Diethylene Glycol in the Epidermis and Dermis of Hairless 
Rat Skin. Dose Applied= 20 µL of 7.93 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 30. 6 34.8 39. 4 34.9 ± 4.40 
Retained 
(µg/G) 
Dermal Wt. 62.5 46.9 26.7 45.4 ± 17.9 
(mg) 
% of Dose 1. 07 0.912 0.588 0.857 ± 0.246 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D . 
Drug 0.664 1. 21 0.679 0.851 ± 0 . 311 
Retained 
(µg/G) 
Dermal Wt. 467.9 385.1 286.6 379.9 ± 90.8 
(mg) 
% of Dose 0.174 0.262 0.109 0.182 ± 0.0767 
Retained 
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Table B.4. In Vivo Retention of Triamcinolone Acetonide 
From Dimethyl Sulf oxide in the Epidermis and Dermis of 
Hairless Rat Skin. Dose Applied 20 µL of 160. 8 mg/mL 
solution applied over 102 cm. 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 1530 1446 931.0 1302 ± 324.3 
Retained 
(µg/G) 
Epidermal 56.8 45.2 52.7 51.6 ± 5.88 
Wt. (mg) 
% of Dose 2.86 2.15 1.62 2.21 ± 0.622 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 34.0 14.5 21. 5 24.3 ± 9.88 
Retained 
(µg/G) 
Dermal Wt. 557.9 875.0 775.0 736.0 ± 162.1 
(mg) 
% of Dose 0.625 0.419 0.530 0.525 ± 0.103 
Retained 
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Table B.5. In Vivo Retention of Triamcinolone Acetonide 
From Ethylene Glycol in the Epidermis and Dermis of Hairless 
Rat Skin. Dose Applied= 20 µL of 2.32 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 52.6 57.2 48.0 52.6 ± 4.60 
Retained 
(µg/G) 
Epidermal 51.1 25.5 55.6 44.1 ± 16.2 
Wt. (mg) 
% of Dose 5.22 2.83 5.19 4.41 ± 1. 37 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug Retained 3.09 0.619 3.52 2.41 ± 1. 57 
(µg/G) 
Dermal Wt. 369.0 299.7 331.1 333.3 ± (mg) 34.7 
% of Dose 2.21 0.360 2.27 1.61 ± 1. 09 
Retained 
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Table B.6. In Vivo Retention of Triamcinolone Acetonide 
From Ethanol in the Epidermis and Dermis of Hairless Rat 
Skin.Dose Applied= 20 µL of 11.6 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 39.6 46.5 22.2 36.1 ± 12.5 
Retained 
(µg/G) 
Epidermal 56.8 36.5 47.3 46.9 ± 10.2 
Wt. (mg) 
% of Dose 1. 02 0.77 0.475 0.755 ± 0.273 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 1.11 1.40 0.700 1. 07 ± 0.352 
Retained 
(µg/G) 
Dermal Wt. 756.0 551.5 638.7 648.7 ± 102.6 
in (mg) 
% of Dose 0.380 0.349 0.203 0.311 ± 0.0945 
Retained 
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Table B. 7. 
From Imwitor 
Skin Layers. 
applied over 
Epidermis 
Parameters 
Drug 
Retained 
(µg/G) 
Epidermal 
Wt. (mg) 
% of Dose 
Retained 
Dermis 
Parameters 
Drug 
Retained 
(µg/G) 
Dermal Wt. 
(mg) 
% of Dose 
Retained 
In Vivo Retention of Triamcinolone Acetonide 
408 R in the Epidermis and Dermis of Hairless Rat 
Dose Applied = 20 µL of 3. 95 mg/mL solution 
10 cm2 • 
Animal Animal Animal Average ± 
1 2 3 S.D. 
29.8 31.4 34.7 32.0 ± 2.50 
29.7 63.9 36.8 43.5 ± 18.0 
1.18 2.68 1. 70 1.85 ± 0.762 
Animal Animal Animal Average ± 
1 2 3 S.D . 
3.06 2.76 4.03 3.28 ± 0.664 
545.7 531.6 612.5 563.3 ± 43.2 
2.23 1. 96 3.30 2.50 ± 0.709 
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Table B.8. In Vivo Retention of Triamcinolone Acetonide 
From Imwitor 412R in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 0.97 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 5.04 5.12 6.5 5.55 ± 0.821 
Retained 
(µg/G) 
Epidermal 28.3 25.0 38.1 30.5 ± 6.81 
Wt. (mg) 
% of Dose 0.804 0.721 1.40 0.975 ± 0.370 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.550 0.690 0.570 0.603 ± 0.0757 
Retained 
(µg/G) 
Dermal Wt. 517.5 552.5 525.4 531.8 ± 18.4 
(mg) 
% of Dose 1. 61 2.14 1.77 1.84 ± 0.272 
Retained 
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Table B.9. In Vivo Retention of Triamcinolone Acetonide 
From Isopropanol in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 1.7 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 6.78 5.06 1.96 4.60 ± 2.44 
Retained 
(µg/G) 
Epidermal 61.0 58.9 73.6 64.5 ± 7.95 
Wt. (mg) 
% of Dose 1. 28 0.926 0.449 0.885 ± 0.417 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0680 0.0860 0.0740 0.0760 ± 0.00917 
Retained 
(µg/G) 
Dermal Wt. 671.1 790.3 694.0 718.5 ± 63.3 
(mg) 
% of Dose 0.143 0.212 0.160 0.172 ± 0.0359 
Retained 
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Table B.10. In Vivo Retention of Triamcinolone Acetonide 
From Isopropyl Myristate in the Epidermis and Dermis of 
Hairless Rat Skin Layers. Dose Applied= 20 µL of 0.095 mg/mL 
Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.843 0.750 0.730 0.774 ± 0.0603 
Retained 
(µg/G) 
Epidermal 25.2 45.6 52.7 41.2 ± 14.3 
Wt. (mg) 
% of Dose 1.25 2.01 2.26 1.84 ± 0.526 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0560 0.0640 0.0620 0.0607 ± 0.00416 
Retained 
(µg/G) 
Dermal Wt. 526.1 536.0 677.8 580.0 ± 84.9 
(mg) 
% of Dose 1. 75 2.01 1.90 1. 89 ± 0.13 
Retained 
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Table B.11. In Vivo Retention of Triamcinolone Acetonide 
From Isopropyl Palmitate in the Epidermis and Dermis of 
Hairless Rat Skin. Dose Applied= 20 µL of 0.07 mg/mL Solution 
Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.754 0.590 0.740 0.696 ± 0.0926 
Retained 
(µg/G) 
Epidermal 28.4 38.4 37.1 34.6 ± 5.44 
Wt. (mg) 
% of Dose 1. 73 1.82 2.20 1. 92 ± 0.249 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.170 0.0460 0.0670 0.0943 ± 0.0663 
Retained 
(µg/G) 
Dermal Wt. 505.4 460.4 474.7 480.2 ± 23.0 
(mg) 
% of Dose 6.90 1. 68 2.54 3.71 ± 2.80 
Retained 
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Table B.12. In Vivo Retention of Triamcinolone Acetonide 
From Isostearyl Alcohol in the Epidermis and Dermis of 
Hairless Rat Skin. Dose Applied= 20 µL of 0.6 mg/mL Solution 
Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 1.42 1.68 1.27 1.46 ± 0.207 
Retained 
(µg/G) 
Epidermal 27.3 24.3 54.8 35.5 ± 16.8 
Wt. (mg) 
% of Dose 0.352 0.371 0.632 0.452 ± 0.156 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug Retained 0.126 0.185 0.109 0 . 140 ± 0 . 0399 
(µg/G) 
Dermal Wt. 609.3 558.3 531.1 566.2 ± 39.7 
(mg) 
% of Dose 0.698 0.938 0.527 0.721 ± 0.206 
Retained 
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Table B.13. In Vivo Retention of Triamcinolone Acetonide 
From Linoleic Acid in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied = 20 µL of 0.135 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.522 0.906 0.678 0.702 ± 0.193 
Retained 
(µg/G) 
Epidermal 44.9 22.7 36.4 34.7 ± 11.2 
Wt. (mg) 
% of Dose 0.919 0.806 0.969 0.898 ± 0.0835 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0510 0.0820 0.0750 0.069 ± 0.0163 
Retained 
(µg/G) 
Dermal Wt. 586.5 632.9 598.0 605.8 ± 24.2 
(mg) 
% of Dose 1.17 2.04 1.76 1. 66 ± 0.441 
Retained 
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Table B.14. In Vivo Retention of Triamcinolone Acetonide 
From Monoacetin in the Epidermis of Hairless Rat Skin. Dose 
Applied= 20 µL of 8.34 mg/mL Solution Applied Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 22.6 16.3 37.7 25.5 ± 11. 0 
Retained 
(µg / G) 
Epidermal 43.5 24.1 65.0 44.2 ± 20.5 
Wt. (mg) 
% of Dose 0.493 0.197 1. 23 0.640 ± 0.532 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.916 0.811 0.467 0.731 ± 0.235 
Retained 
(µg/G) 
Dermal Wt. 633.5 413.5 635.9 561.0 ± 127.7 
(mg) 
% of Dose 0.292 0.168 0.149 0.203 ± 0.0777 
Retained 
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Table B.15. In Vi vo Distribution of Triamcinolone 
Acetonide From Miglyol 812R in the Epidermis and Dermis of 
Hairless Rat Skin . Dose Applied = 20 µL of 0. 25 mg / mL 
Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 2.47 3.75 2.77 3.0 0 ± 0.669 
Retained 
(µg / G) 
Epidermal 41. 4 27.8 22.3 30 . 5 ± 9.83 
Wt. (mg) 
% of Dose 1.23 1.25 0.718 1. 07 ± 0.302 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0 . 20 0.19 0.32 0.237 ± 0.0723 
Retained 
(µg/G) 
Dermal Wt. 524.0 521.0 589.1 544.7 ± 38 . 5 
(mg) 
% of Dose 1.28 1.17 2 . 24 1.56 ± 0.589 
Retained 
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Table B.16. In Vivo Retention of Triamcinolone Acetonide 
From Miglyol 840R in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 0.35 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 6.10 5.40 5.26 5.59 ± 0.450 
Retained 
(µg/G) 
Epidermal 46.3 45.2 62.9 51.5 ± 9.92 
Wt. (mg) 
% of Dose 2.39 2.10 2.84 2.44 ± 0.373 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.580 0.530 0.630 0.580 ± 0.0500 
Retained 
(µg/G) 
Dermal Wt. 651.7 598.7 551.3 600.6 ± 50.2 
(mg) 
% of Dose 3.23 2.72 2.99 2.98 ± 0.255 
Retained 
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Table B.17. In Vivo Retention of Triamcinolone Acetonide 
From Oleic Acid in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied = 20 µL of 0.095 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.539 0 . 302 0.463 0.435 ± 0.121 
Retained 
(µg/G) 
Epidermal 17.2 53.1 21.7 30.7 ± 19.6 
Wt. (mg) 
% of Dose 0.537 0.928 0.581 0.682 ± 0.214 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0660 0.0400 0.0360 0.0473 ± 0.0163 
Retained 
(µg/G) 
Dermal Wt. 613.6 629.3 724.0 655.6 ± 59.7 
(mg) 
% of Dose 2.36 1. 45 1.49 1. 77 ± 0.514 
Retained 
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Table B.18. In Vivo Retention of Triamcinolone Acetonide 
From PEG 200 in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied = 20 µL of mg/mL Solution Applied Over 10 cm2 . 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 8.05 3.27 6.70 6.01 ± 2.46 
Retained 
(µg/G) 
Epidermal 26.3 42.1 46.8 38.4 ± 10.7 
Wt. (mg) 
% of Dose 0.106 0.0690 0.156 0.110 ± 0.0437 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.310 0.210 0.160 0.227 ± 0.0764 
Retained 
(µg/G) 
Dermal Wt. 766.8 499.7 519.8 595.4 ± 148.7 (mg) 
% of Dose 0.119 0.0520 0.0410 0.0707 ± 0.0422 
Retained 
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Table B.19. In Vivo Retention of Triamcinolone Acetonide 
From PEG 300 in the Epidermis and Dermis of Hairless Rat Skin. 
Dose Applied= 20 µL of 7.75 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 1.13 2.86 1.90 1.96 ± 0.867 
Retained 
( µg/G) 
Epidermal 38.7 32.2 46.0 40.0 ± 6.90 
Wt. (mg) 
% of Dose 0.0250 0.0520 0.0500 0.0423 ± 0.0150 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.140 0.170 0.140 0.150 ± 0.0173 
Retained 
(µg/G) 
Dermal Wt. 702.5 429.7 609.3 580.5 ± 138.7 (mg) 
% of Dose 0.0560 0.0400 0.0430 0.0463 ± 0.00850 
Retained 
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Table B.20. In Vivo Retention of Triamcinolone Acetonide 
From PEG 400 in the Epidermis and Dermis Hairless Rat Skin. 
Dose Applied = 20 µL of 6.55 mg/mL Solution Applied Over 10 
cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.190 0.340 0.800 0.443 ± 0.318 
Retained 
(µg/G) 
Epidermal 55.7 26.8 49.1 43.9 ± 15.1 
Wt. (mg) 
% of Dose 0.00600 0.00500 0.0220 0.011 ± 0.00954 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.139 0.128 0.130 0.132 ± 0.00586 
Retained 
(µg/G) 
Dermal Wt. 665.1 590.5 652.0 635.9 ± 39.8 
(mg) 
% of Dose 0.0520 0.0430 0.0470 0.0473 ± 0.00451 
Retained 
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Table B.21. In Vivo Retention of Triamcinolone Acetonide 
From Propylene Glycol in the Epidermis and Dermis of Hairless 
Rat Skin. Dose Applied= 20 µL of 6.06 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 153.5 197.6 138.1 163.1 ± 30.9 
Retained 
(µg/G) 
Epidermal 24.3 26.7 48.9 33.3 ± 13.6 
Wt. (mg) 
% of Dose 3.61 5.11 6.54 5.09 ± 1.47 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 3.24 0.962 2.06 2.09 ± 1.14 
Retained 
(µg/G) 
Dermal Wt. 341.7 308.6 475.5 375.3 ± 88.4 
(mg) 
% of Dose 1.07 0.287 0.950 0.769 ± 0.422 
Retained 
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Table B.22. In Vivo Retention of Triamcinolone Acetonide 
From Triacetin in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 1.9 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 2.69 1.66 1.27 1.87 ± 0.734 
Retained 
(µg/G) 
Epidermal 38.0 33.1 39.l 36.7 ± 3.19 
Wt. in mg 
% of Dose 0.233 0.125 0.113 0.157 ± 0.0661 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.149 0.156 0.109 0.138 ± 0.0254 
Retained 
(µg/G) 
Dermal Wt. 717.8 553.8 590.8 620.8 ± 86.0 
in mg 
% of Dose 0.243 0.197 0.147 0.196 ± 0.0480 
Retained 
161 
Table B.23. In Vivo Retention of Triamcinolone Acetonide 
From Tributyrin in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied = 20 µL of 0.095 mg/mL Solution Applied 
Over 10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.838 0.727 0.901 0.822 ± 0.0881 
Retained 
(µg/G) 
Epidermal 47.5 40.2 26.2 38.0 ± 10.8 
Wt. (mg) 
% of Dose 2.12 1.55 1.25 1. 64 ± 0.442 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0530 0.0550 0.0380 0.0487 ± 0.00929 
Retained 
(µg/G) 
Dermal Wt. 379.5 412.5 495.4 429.1 ± 59.7 (mg) 
% of Dose 1. 07 1.20 0.988 1.09 ± 0.107 
Retained 
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Table B.24. In Vivo Retention of Triamcinolone Acetonide 
From Tricaprylin in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 0.30 mg/mL Solution Applied Over 
10 2 cm. 
Epidermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 3.56 2.73 2.13 2.81 ± 0.718 
Retained 
(µg/G) 
Epidermal 25.9 35.4 48.7 36.7 ± 10.5 
Wt. (mg) 
% of Dermis 1.53 1. 60 1. 72 1.62 ± 0.0961 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0800 0.0850 0.0790 0.0813 ± 0.00321 
Retained 
(µg/G) 
Dermal Wt. 535.0 560.8 471.9 522.6 ± 45.7 (mg) 
% of Dose 0.686 0.791 0.620 0.699 ± 0.0862 
Retained 
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Table B.25. In Vivo Retention of Triamcinolone Acetonide 
From Transcutol in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 6.63 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 42.0 53.3 37.7 44.3 ± 8.06 
Retained 
(µg/G) 
Epidermal 26.7 26.1 48.9 33.9 ± 13.0 
Wt. (mg) 
% of Dose 0.822 1. 02 1.35 1. 06 ± 0.267 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 2.10 1.66 0.883 1.55 ± 0.616 
Retained 
(µg/G) 
Dermal Wt. 479.7 586.7 610.8 559.1 ± 69.8 
(mg) 
% of Dose 0.736 0.712 0.398 0.614 ± 0.190 
Retained 
164 
Table B.26. In Vivo Retention of Triamcinolone Acetonide 
From Triolein in the Epidermis and Dermis of Hairless Rat 
Skin. Dose Applied= 20 µL of 0.11 mg/mL Solution Applied Over 
10 cm2 • 
Epidermis 
Parameters Animal Animal Animal Average ± 
1 2 3 S.D. 
Drug 0.799 1.70 1.45 1.32 ± 0.465 
Retained 
(µg/G) 
Epidermal 29.0 22.4 53.8 35.1 ± 16.6 
Wt. (mg) 
% of Dose 1. 09 1. 80 3.65 2.18 ± 1. 32 
Retained 
Dermis 
Parameters Animal Animal Animal Average ± S.D. 
1 2 3 
Drug 0.0220 0.0730 0.0460 0.0470 ± 0.0255 
Retained 
(µg/G) 
Dermal Wt. 501.6 258.5 475.0 411.7 ± 133.3 
(mg) 
% of Dose 0.51 0.886 1.03 0.809 ± 0.268 
Retained 
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